CA2219705A1 - Solid pharmaceutical preparation - Google Patents
Solid pharmaceutical preparation Download PDFInfo
- Publication number
- CA2219705A1 CA2219705A1 CA002219705A CA2219705A CA2219705A1 CA 2219705 A1 CA2219705 A1 CA 2219705A1 CA 002219705 A CA002219705 A CA 002219705A CA 2219705 A CA2219705 A CA 2219705A CA 2219705 A1 CA2219705 A1 CA 2219705A1
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutical preparation
- solid pharmaceutical
- weight
- parts
- disintegrant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Abstract
Disclosed is a solid pharmaceutical preparation comprising a pharmaceutically active ingredient, erythritol, crystalline cellulose and a disintegrant, which exhibits fast buccal disintegratability and dissolubility.
Description
'97~10~21~ 19~00~;TAKEDA PATENTS OSAKA Fetherst~n ; 8163006601;# 4/27 .
So~ld Pharm~ceutical Prep~r~tion ~ac~rolln~ of th~ Inven~
The pre~en~ inventlon r~lstes t~ a solld S pharm~ceu~ic~l pr~paration, esp~cially ~ buc~l di~olution type ~olid prep~ration hAvlng ch~racterist~cs of fAst dlsintegr~tion or di~solutlon in the or~l cavlty even witho~t w~ter.
Generally, ~olld ph~rm~ceutlcal prop~ratlonR ~uch ~Y ta~let~ ~re de~lgned ~o th~t afte~ thoy ~re or~lly ~dminl~tored, they disintegratè or dis~olve $n the dige~ive org~n~ ~nd the rhA~ceut~cally ~ctive ingredients ~re ~beoxbed. Accordlngly, f~st d~integrat$on or dl~olution ln the or~l c~vl~y ie no~
a ~ommon design feature.
How~ver, $n ~ccordance with the incr~ae ln the aged population and ch~nge ln life ~tyle~, there ha~
b~n a nee~ for developmont of buccal di~aolutlon type ~oli~ prep~r~tion~ whlch ~n be, lf necessary, 2C admini~tered readily even without ~ater, by aged people and children anywhere or ~nytime, ~aintalning the convenl~nce typ1c~lly a~orded ~y ph~r~ceutic~l ~abl~t~.
A~ th~ t~hnlque for prod~cing prepa~tion~ ~hich 2s ~ickly di~ntegra~e-or dlssolve in the or~l CAvity, horetofo~b, there hn~ been pr~posed ~ metho~ for produclng preparation~ by dis~olving or su~pend~ng pharma~eutlc~l or medicinal ingredlent~ in ~n ~queo~
~olvent, filling ~he re~ultant ~olution o~ su~pension ln~o ~ pocket molded ~eforeh~nd ln ~ bllR~rp~ck ~nd r~duclng wa~er content from ~h~ ~olu~ion by f~eeze-drying or v~cuum ~ryin~ [usp 4371516~Examined Jap~nese Patent Applic~tlon Publlcs~ion ~okoku) No. 62~1~87)-50445), ~/o 93~12769)(Publication of Tr~n~lations o~ ~.
International P~tent Applic~tlon. No. 5-812?6~)]. This metho~, howe~or, ha~ problem~ in tha~ it take~ time for 97~10~21~ 19~00~;TAXE~A PATENTS OSAKA FetherstAn ; 8163006601;# 5/27 m~nufacturing ~nd in that the ol:~tained product~ h8ve in~ufflcient ~trength and thus are ~ifficul~ ~o handle.
Thero is known another method in whlch ~ mixture of phe -ceuti~ally ~ctlve ingrediont wlth ~ low 5 moldBbillty 8AC~haride i8 g~nul~ted with a hîgh molda~ y sac~h~ride added thexeto ~EPA 745382, (Public~Lon of 'rrzln~lat~ on~ o~ In~ernation~l Patent AppllcA~cion No. 7-8203B0 (WO 95t203~0) ) ] . The product obtained by thi ~ method h~s ~uch hArdne~ that the do~age form re~in~ w~thout ~eing dlslntegr~ted ~n the course of di~trlbutlon, whlle the method has a pr~lem ~hAt t~bletting i~ not e~sy, a~ is of~en th~ case with high molds~ility ~ccharide~, be~au~e t~bletting i8 ~arrie~ out with ~ower pre~sure. Also the product~
lS ha~e an ~dditional d~fect that they le~ve ~ problem ~o b~ ~olved in term~ of buccal f~gt dislntegration and dio~olution. On the other hand, there have been made ~tudl~s of ~ucc~l dl~olution preparation~ produced by wetting molding. But, 1n qeneral, t~blet~ hAving fast di~integr~tion o~ di~solution h~ve dçfect~ of l~ç~ ln ~trength.
F~om the foregolng view-polnt, there h~oe ~een a need or dem~nd for d~velopment of prep~r~tion~ which exhi~lt excellen~ buccal di~integration and dissolution ~5 and al~o an ~pprop~late ~trength such that the prep~ration~ never di~inte~r~te or ~uffer dam~ge ln the cour~e of the production ~ep~ ~r dlstributlon ~t~ges.
J~panese Patent Appllcations Laid-open No~ 2~B627, 1-26862~ ~n~ 8-2703~ de~cri~ n pha~ceu~lc~l prep~ra~lon or compo~i~ion conta$ning erythritol, but fail to de~cribe ln~r~buccal ~ olutlon type prepar~tion~.
Th~ ln~r~ntlon provideb ~ol~d ph~rmace-utlcal p~ep~rat$on~ whl~h c~n be re~dily adminiEtered even withou~ w~ter, e~pecially ~olid ph~m~ceutlcal prep~r~tions wh~ch qulck~y disinteg~ate and ~ ol~e in '97~10~21~ 19~00~;TAKEDA PATENTS OSAKA Fetherst~n ; 8163006601;# 6/27 the oral cavlty.
Summ~Jy of the Irlvent1n~
A~ ~ re~ult of inten~1~e ~tudles and r~sear~hes, the pre~ent inventors found ~hat the prep~ration~
compr~i8~ng th~ p~rtlcul~r thr~e ln~redient~, erythritol, cry~talltno ~ellulose ~nd ~ di~lntegrant, in addit~on to a ph~rmaceutl~lly act~e or medicinal ingred~ent, have characte iEtiC~ of fa~t dislnteqr~t~ng andJor di~solvlng in the oral cav$ty, foll~wed by furt~er ~tudie~, which wa~ led to complet~on of the pre~en~ inventlon.
~ hat i~, thls lnvention rel~to~ to ~1) a ~olid pharmace~tical prep~ratlon ~omprislng (i) ~
pharm~coutically ~ctlve ingredlent, (ii) erythritol, ~iil) cry~talllne cellulose ~nd (iv) a di~n~gr~nt;
~2) the solid pharmaceutlcal pr~paratiOn in ( 1 ) ~ whlch 18 capable of buc~al di~integra~lon or dl~olutlon; (3) the ~olid phP~---seutlcal preparation in ~1), which fu~ther comprl~e~ mannitol; ~4) the solld phanm~ceu~ic~l prep~r~tlon in ~1), whorein the di~integrAnt 1~ c ~_~o~$done; (5) the ~oltd pha~m~ceutl~l prepar~tion in (1), wherein crythritol 18 ~ontained ln ~ proportion of S-90 part~ by we1ght, Z5 b~ed on 100 part~ by weight of the sol~d phArm~ceutical preparatlon; ~6) ~he ~olid pharmaceutical prep~rat~on in (lj, wherein the cry~tAilin~ cellulo~e 1~ ~ont~lned in a proportlon of 3-50 pnrts by weight, ~as~d on 100 parts by we~ht of the s~lld ph~rmaceu~ical p~ep~ratLon; 171 th~ ~olid pharm~c~uti~l p~ep~ratlon in (1), wherein the dl~integ~snt is contained in ~ proportion of 1-10 part~
by ~e~ ght, ba~ed on the ~olid pharmaceutical prep~ration; (8) the ~olid pharmA~utlcal prepa~tlon 3S ln (1), wherein the in~redientR, (i) a pharmaceut~cally aotive ingredient, (ii) erythritol, ~iii) cry~talline '9~10~21~ 19~00~;TAKEDA PATENTS OSAKA Fetherst~n ; 8163006601;# 7/27 cell~los~ and (iv) a di~integrant, ~re unlformly mixed, pre~e~bly ~hroughout the prepa~tion; (9) the ~olid phsrInacoutical prep~ration in (1), which iY a tablet;
(10) a sol~d pharma~eutlcal prepar~tion ~apablo of buccal disintegr~tion or di~solut$on, which comprises 0.3-S0 p~rt~ by welght of (1) a ph~r~eutlcally Actlve ingredient, 50-~0 par~ by weight of (il) erythri~ol, AnCl 5-~0 p~ts ~y ~eight of ~ c~yst~llino cellulo~o and 3-7 part~ ~y weight of (iv~ a disintegr~nt; (11) the ~olid pharmaceutical preparatlon in (1), wherein the ph~rmaceutlcally actlve $ngred~ent i~ ~n antldinics o~ 8 drug ~o~ klneto~is or ~otion sl~ne~ 12) a metho~ of improvinq buccal ~ieintegr~tion or ~i~solution of ~ ~olid pharmAceutical preparation cont~inlng 11 ? A phA ~utically active lngredient, whlch compr~se~ lncorpor~tln~ (ii) ~ythritol, (i~i) crystalllne collulo~e ~nd ~iv) ~ dlsln~egr~nt ln combinatlon in the ~o~ld ph~rmac~utic~l prepAr~tion;
~13) u~e of a combin~tlon of (L$) erythrltol, tlli) cry~Alllne cellul4s~ ~nd (iv) ~ dl~integr~n~ fo~ ~he production of ~ ~olid phA-~-~ceu~lcal pxeparation comprl~ing (i) ~ ph~m~ceut$c~11y aCtiv~ i~ ent, with imp~oved bucc~l di8integ~blllty ~nd/or di~olubil~ty; ~14) u~e of ~ composi~lon comp~i~lng ~i~
a ph~- ~eut$cslly activa 1ngI~edient, (~i) erythritol, (il$) crystalllne ~ellulos~ and ~iv) a ~i~integrant for the production of a ~olld ~ Aceutical preparation impr~ved with bucc~l d$sintegra~illty and~o~
di~olu~ility; (15) a method of inhlbiting or treating ~ di~e~e of ~ su~e~t ln n~ed th~reof, which comprl~e~
~dmlni~ter~ng to the subject an effect~ve ~mount of (1) a pharm~ceuti~lly ~tive ingrediont for th~ di~e~e as ~ ~olid ph~lrmaceut~c~l pr~par~i~n ~ont~inlng ~ii) erythr~ol, (iii) cry~t~lline ~ellulo~e ~nd ~iv~ a 3S dl~integrant ln a~ditlon to t~e pharmaceutiç~lly ~ctive ingredi~nt (1~, with improved buccal dl~integrabllity '91~10~21~ 19~00~:TAKEDA PATENT~ OSAKA Feth~rst~n ; 8163006601;# 8/27 ~nd/or di~olu~ility; [1~) a method of m~king a ~o~id ph~rm~ce~tic~l prep~ration, whlch comprlse~ bl~nding a ~ixture of (1) a ph~rmaceutlcally ~ctiv~ lng~edient, ~ii) orythritol, (iil) cry~talllne coll~lo~e and ~iv) disin~egrant, ~nd produ~ing the ~olid pharmaceutical preparatlon from the mixture; an~ (17) th~ metho~
according to t16), wheroin the sol$d preparatlon di~olves completely in ~olely buc~l s~liva within 1 minut~ of admini~tr~tlon to a patient.
D~tA1 1P~ C~1~t;0rl of ~ Inve~ttn~
The ph~rmace~tic~lly ac~ive or me~lcinal tng~edlent-to b~ u~ed in the preRent invention m~y be in ~ny optional form, ~or example, a ~olid, powder or gr~nular, cr~stalline, oily ox ~o~uti~n form.
There 1B no limitation to ~he ph~rmAceutic~lly ~ctive lngredlen~ to be used. As the ph~rmaceutic~lly ~ctlve ingredi~nt, for ~x~mple, the~e may be mentioned one or more ~eM~rs ~ele~ted from ~he group con~i~tlng of nouri~hlng ~nd heal~h-promoting ~gents, anti-pyretlc-analge~ic-~ntlin~l~mmatory agents, ~ an~ip~ychotic drug~, anttAnyiety drug~, ~ntidepressant~, hypnotic-~edative~, ~pa~molytic~, gastrolnte~tinal function conditioning nyent~, antacld~, ~nt1tu~ive-exp~c~orant~, dental buccal drug~, an~lhi~tamines, cardiotonlcR, ~ntlarrhythml~
drugs, d~ure~ic~, antihypertensive drug~, v~ocon~trlctor~, co~on~ry vasodlla~o~, peripheral v~odilators, cholagogue~, antibiotlcs, chemother8peutlc ~rug~, ~ntidiabetic agent~, dru~s for ~teoporo~is, skoletal muscle rel~xant~, ant~dinic~ o~
dru~ for ~in~to~i~ or motion pickness and the llke.
~ x~mples of th~ nou~i~hinq and ~al~h-promoting agent~ include vitAmin~ such a~ vitamln A and lt~
deriv~tive~, vl~min D and its de~ivatl~eR, vitamin E
and it~ deriv~tives (d-a-tocopherol aceta~e etc~)~
'97~10~21~ 19~00~;TAKEDA PATENT~ OSAKA FetherstDn ; 8163006601;# 9/27 vl~Min ~1 and its der~va~l~e~ ~di~enzoylthi~m~ne, fur~ul~iamine hydro~hloride e~.), vitamin ~z and it~
~erivatlves (riboflAvin butyrate etc.), vitamln Bh ~nd lt~ deriva~l~es (pyr1dox$n~ hydrochloride etc.~, vit~mln C and its de~iv~tlvos (asco~bic ~cid, ~odium ~-~corba~e etc.), vi~amin ~1~ and lt~ derivatlve~
~hydroxocobal~mln acet~te etc.), etc., a~ w~ll a~
mlner~ls such ~ calcium, magne~lu~ And iron, prote~n8, amino ac$d~, oligo~acch~ride~, crud~ drug~ ~nd the like. Example~ of th~ ~ntlpyretic-analgesic-ant~in~l~mmato~y ~gent~ include, asplrin, acet~minophen, ~thenz~mi~e, i~uprofen, diphen~y~r~mlne hy~rochlorid~, dL-chlorphenlramlne m~le~te, dihydrocod~ine pho~phate, no~capine, methylephedrlne hydrochloride, phenylpropanolamlne hydrochlor5~e, caffeine, anhy~rous caffeine, ~erratiopeptldase, ly~ozym~ chloride, tolfenamic ~c~d, mefenamic acid, diclofenac ~odLum, flufenamlc ac~d, ~a~lcylamide, am~nopyrlne, ketoprofen, ~ndometh~cln, bucolome, pentazoc!ine and ffo on.
Ex~mples of the an~ip~ychotlc ~l~ug9 lnclud~
chlorpromazine, re~erpln~ and 80 on. Example~ of the anti~nxlety drug~ include chlordl~2epoxide, diazepam, etc. Example~ of the an~$depre~snt~ Lnclud~
2S lmipramine~ maprotillne, ~mphetaminc and ~o on.
Example~ of the hypnotic-~ed~tives include e~t~zol~m, nitrazep~m, di~z~p~m, ph~nobarhital sodium and ~o on.
~5xamples of the sp~3mol~tic~ lncludo ~copol~mlne ~ydro~romide, diphenh~mlne hydrochloride, p~p~verine hydrochlorlde And 90 on.
Example~ of the gastrointestinal functlon condlt1 onlng agen~ include stomachic-d1gestlve~ ~uçh ~B d~a8te~Q, anc:charated pop~n, ~copoliu ~xtr~ct, lipa~e AP, cinnamon oil, etc., lntest~n~l func~ion con~oll$ng dru~ ~uch ~ h~r~rine çhloride, re~istant lactic ~cid b~terlu~, Lacto~Acillu~ ~ifidu~ and ~o on.
'97~10~21~ 19~00~;TAKEDA PATENTS OSAKA Fetherst~n 8163006601:#10/27 ~xample~ of the ant~ci~ include magne~ium c~bonate, ~odium hydrogen carbonate, magne~ium alum~nometasillc~te, synthet~c hydrotalc$te, prec~pit~ted c~l~ium carbon~te, magn~sium oxide and ~o on.
Exnmples of the anti~u~ive-expeotorAnt~ lnclude chlopera~ti.no hydrochlori~e, d~xtromethorph~n hydrobromide, t~eophylline, pota~ium guaiacol~ulfonate-, gu~ifenesin etc. Example~ of the dental bucc~l drug~ lnclud~ o~ytetracycline, trlamcinolon~ ac~tonl~, ohlorhexldine hydrochloride, lidoc~ine ~nd ~o on.
Example~ of the ~ntlhl~tam~n~ incl~de diphenhy~r~mlne hy~rochlorlde, promethazlne, i~othipendyl ~t~hlorlde, dl-chlorphenir~mlen malo~to, etc. Exa~ple~ of the cardiotonlc~ include etllefrine hydrochlorid~ J~nd 80 on. Exalnple~ of the anti~rryhythmic drug~ include pro~aln~mide hydrochlorldo, propr~nolol hydrochlor~de, pindolol snd 90 on. ExampleE~ of the d~uretic~ include i~o~or~ide, furosemide and 80 on. Ex~mple~ of ~he ~ntihyperten~lve dru~ include delaprll hydrochloro~ido, ~aptoprll, hexa~othonlum bromlde, hydrala~ine hydrochlorlde, l~bet~lol hy~rochlorlde, methyldop~ and the l~ke.
Ex~mple~ of the ~80con~trictor~ ~nclude phenylephrine hydrochlo~id~, etc. Example~ of the coronary v~sodil~tora include car~o~romen hydrochlorlde, mol~ldomine, verap~mil hydrochloride ~nd ~o on. Ex~mplç~ of the peripheral vnsodllator~ lnclude cinnar~zino and ~o an. ~xample~ of the eholagogues includq dehydrochoLic ~cld, treplbut~no and Ra on.
~xample~ of the antibiotlcs in~lude c~phe~, penem~ and ~rbapene~ uch a-s cef~lexin, ~moxLc~llin, p$vmecillin~m hyd~ochlorido, cefotism dlhyd~ochlorlde etc. Examples of the chemothe~apeutl~ ~rug~ lnolude ~lfamethl~ol~, thiazo~ulfone and ~o on. Examples of '97~10~21~ l9~00~;TAKEDA PATENTS O~AKA Fetherst~n ; 8163006601;#11/27 the an~idi~bet~c ag~nt~ inc~ude tol~ut~mi~e, vogllbo~e and ~o on. Ex~mple~ of the drug~ for o~teoporo~ls include ip~iflavone ~nd 80 on. Examp~e8 of the skeletal ~u~cle rel~xant~ in~lude methoc~rb~mol and ~o on. Exa~ple~ of the Antidin$c~ or drug~ for kinetosi~
or motion sickne~, i.e. ~ntimotlon ~icknes~ drug, include meclizine hy~rochlorldç, di~enphydrin~te and ~o on.
The ph~rmac~u~ic~l~y ac~i~e or medicin~l lngredient may l~o ~iluted w~ch a dlluent which 18 u~ed generally in th~ pharmaceutical or food indu~try. At le~t one o~ the pharm~ceutlcally ~otive lng~edien~s may ~e ln ~n ol~y form, Among ~uch pharm~ceuti~lly active ingredients, preferred ex~mple~ for purpo~ of the p~esent invention a~e vit~mln~, crude drugs, antip~rotic-analgesic-an~iinflamm~tory Agent~, ~ntLanxioty drugs, hypnotic-sedative ~gent~, gas~rointestlnal func~ion conditioning agent~, anti~u~81~e-e~pec~or~nt~, ant~hyperten~1ve drugs, antidlabetic~, drl~gs for o~teoporo~i~, skeletal muocle rel~xant~ and antidlnlc~
Or drugs ~or kineto~l~ or motlon sickneR~.
Espec$~11y prefer~le ac~ive ingredientR for t~e ~:pr~sent inventlon ~re~an~idinlc~ o~ drugs for klnetosi~
or motion sit:kness in that suc~h drug~ ~re often r~q~red to be adminietered without water for prev~ntlon or tre~tment of ~ine~06i~ or motion ~icknos~.
The ~ol$d pharm~ceutical prepar~tions of thç
present inventlon cont~in the ~bove-mentioned ph~rmaceutic~lly activ~ or me~icinal ingredi~nt~
u~ually in a propo~tion of about O.05-700 by we1~ht, pr~afer~bly about O.1-50~ hy ~eight, more prefer~bly 0.3-30~ by welght.
Eryth~itol to be u~ed ~ one of the ra~ materiAls for the prep~ra~ion~ of t~e pre~ent inventlon i~ a kind 97~10~21~ 19~00~;TAKEDA PATENTS OSAKA Fetherst~n ; 8163006601;#12/27 of ~ugar ~lcohol and ia in ganer~l produced by ferm~ntation wl~h yea~t~ u~lng gluco~e a~ the ~t~rting m~teri~l. U~u~lly, ery~h~itul product~ h~v$ng a pA~ticle size capAbl~ of p~s~ing throu~h a 50 m~h 5 8ieve ~re used. These pro~uCt~ ar~ available on the m~r~et, and examples of ~uch produc~ include ~rythritol ~nufactu~ed by Nikken Chemical Co., ~td.
Erythrit~l is lncorpor~ted ln a proportlon of About S-90 part~ ~y ~eight, prefe~ly About 10-80 t 0 p~rts by weight, more preferably ~bout 50-80 p~rts by wç~ght, ~ed on 100 p~t~ ~y weigh~ of the ~olid pharn~ceutic~l prepa~ation.
The preparat$on of the pre~ent invention prefçr~bly compri~e~ cry~talline çellulose, whlch iq al~o c~lled ~icrocry~talline cellulo~e, and typically ~uch c:rystalline cellulo~e tha~ i8 produced by ~rtially depolymerizin~ ~-cellulo~e ~nd purifying the resultant polymer can be u~ed.
Ex~mple~ of the cry~talllno c~llulo~o to be u~ed 1n the pre~ent lnvention lnclude products o~ Yariouo gr~de such ~-CEOLUS KG801, ~vicel PH101, av~cel PH102, avicel PH301, avicel PH302, ~vicel RC S91 (crystall1ne c:~llulase c~rmelloele ~odlum) ~nd 80 on. A~ the crys~alline cellulo~e, one ~pecle~ m~y be used oingly or altern~tively two o~ more ~pe~ie~ may be used in ~omblnation. Moro pre~e~red ~xample~ of the crystalline cellulo~e ~re CEOLUS gG8nl which iB calln~
~vicel of hlgh comprossi~illty. ~hesa r~w materl~ls are ~vall~ble on tho market, ~hlch ~re exempllfied by ~ho pro~ts manufac~ur~d ~y A~shi Chemic~l Co., Ltd.
C~ry9t-~lllne cellulo~e i8 ~ontalned in 1l propo~tion of about 3-50 parts by weight, prefor~bly ~bout 5-40 par~B by wei~ht, ~re prefnr~bly ~hout 5-20 part~ by welght, ~ase~ on 100 p~rts by wolgh~ of the solid E'll'IA AC!~UtiC~,l prepArRtion-As the diainteg~nts to ~e used fo~ the pre~qnt '97~10~21~ 19~00~;TAKEDA PATENTS OSAKA FetherstAn : ~163006601;#13/27 1~1 ~ inven~lon, unle~ the ob~ct of ~he invontion ~8 interfored wlth, ~ny d~integrant~ ~hi~ are ~n common u~e in the pharm2~eutical f1lod. Example~ of most pr~fe-r~d dl~i~t~gr~nte i~lude tho~e known a~ super dln~n~egrant su~:h ~ cro~povidone ~ISP Inc., B~SF), croscarmello~, cl~-A~nmollo~e ~odium (FMc-A~ah$
C~emical ~o., Ltd.), car~ellose c~lcium [~otoku Chemicsl ~Yakuhin) ] . ~ther prefe~d example~ of dl~lntegran~s inclu~e carboxymethyl~t~rch ~odium ~at~utani ~hemic~l ~o., Ltd.l, low ~ubstituted hyd~oAyy ~yl cell~lo~e (Sh~n-Et~u ¢hemiçal Co., Ltd.), ~orn ~tarch ~nd ~o on. The~e dislnte~rantb can be u~ed ~ingly or two Or more ~pecie~ c:an be u~ed in combin~tion. For ex~mp~e, prefera~ly, cro~povldone m~y be used ~ingly or in combinstion with other dlsintegran~. Here, 80 ~ro~po~idone, any c~o~-linked homopolymer cslled 1-ethenyl-2-pyrrol~inone homopolymer may be used, ~nd usually cro~po~i~one h~ving ~ molecul~r ~eight o~ ~,000,~0 o~ more.
Sp~cl~i~ example~ of cro~po~idone ava~l~blo ~ n th~
m~rke~ inclu~e ~ross-lln~e~ povidone, Kollidon C~, Polyp~a~done Xh, Polypla~done X~-10, INF-10 (manu~actured by ISP), p~lyvlnylpoly~ olidone, PVPP
~nd l-vinyl-~-py~olid$none ho~opolymer.
These ~:lisintegr~nts ~r~ u~uslly lnco~por~ted in proportion of a~out 1-15 p~ts by welght, prefer~bly About 1-10 p~rt~ ~y welght, more prefer~bly 4bout 3-7 p~rts by wel~t~ ba~ed on 100 p~t~ by welght of the Jolld pharm~ceutic~l prep~rAtlon.
. In the present invention, in ~dd~tion to the a~ove-m~ntioned ingre~ientn, ~annltol c~n b~ furth~r ad~ed. Mannitol ~vail~ble on t~e market can be employed, an~ ~uch m~nnltol 1B exempllfied ~y the prod~ct m~nufactured by Tow~ Ch~mLcal ~a~ei~ Co., Ltd.
3S U~u~lly, mannitol L~ employed wlth ~ partlclo ~iz~
capable of pa~ing th~eugh ~ lso-me~h ~ieve.
'97~10~21~ l9~00~;TA~EDA PATENTS ~AKA ~eth~rstAn 8163006601;#14~27 ~he ~olld phAr-"~ceutlc~l prepara~ion~ of the pr~sent t nvention are u~eful especially ~ buccal ~is~o~ution type solid prep~rations, which, t~lough in a ~o}ld fonm, ~f~e~ or~lly admini~tered, intr~bucc~lly dl~olve or di~integr~te withou~ being ~wnllowed. As the do~ge form of the ~oli~ prepara~ions, there may be generAlly mentioned granule~, ta~le~s and the like.
More prefe~le do~age forms of the ~olicl prepar~tiOns of the present inven~ion ~re t~let~. Such t~letB are characterized in that they ha~ ~pp~opr1ate h~rdneB~.
Unle~s the ob~ect of the invention 1 B intQrfe~ed with, the abov~ -nt~oned preparation of ~he pre~en~
inventlon m~y furthor cont~in ~ variety of addltivee ~hich ar~ commonly employe~ in the m~nuf~cture of prepar~tion~ ln qeneral do~g~ fo~m~.
The addi~lves mentioned ~ove ~nclude, among . others, binder~, ~clds, fo21snlng ~en~, altif~clal ~weeteners, flavorants, lubrlcant~, colorAnts ~nd ~o on .
Example~ of the binder~ ~nclude hydroxyprop~l~ellulo8e~ hydr~y~ u~ylmethylcellulo~e~
a-starch, polyvlnylpy~r~lidone, gum arAbic powdQr, gela~in, pullulan ~nd the like.
Ex~nple~ of the aclds includo citrlc acld, t~rtari~ ~cid, ~nd Ine.lic ~cid ~nd 80 on. Ex~mple~ ~f t~e foamlng agent~ ln~lude ~od$u~ hydrogen ca~bonat~
and 80 on. Ex~mplee of t~o nrt~fioial ~weetener~
~nclude ~accharin ~odium, dipot~lum glycyrr~izinate, ~part~me, ~tevia, th~umatln and so on. Ex~mple~ of thc flavorantR lnclucle lemon, lemon lime, orAnge, m~nthol and the li~e. Ex~mple~ of the lu~rlc~nt~
lnclud~ magnesium ~te~ate, eucro~e fatty ncld e~ter, p~ly~t~ylenegl~col, t~lc, ste~ric a~id ~nd th~ li~.
Example~ of the colorant~ include v~riou8 food color8nt~ e.g. FD~C Yellow No. 5, F~&C ~ED No.2, Fn~c Blue No. 2, e~c., foo~ lake~, red iron ox~de ~n~ ~o on.
'97~.0~21~ 19~00~;TAKEDA PATENTS OSAKA Fetherst~n 8163006601;#15/27 .
Preferably, the 801i d pharmac~uticsl preparatlon of the pr~ent ~nv~ntion ~ompri~es the above-men~ioned ingredlents homogeneou~l~ or uniformly In other wordR, ~ho ingredlent~ ~ro p~efer~ly intimately ~nd uniformly mixed throughout tho prep~ation.
The ~olid pharmacoutical preparation ~ccordlng ~o the pre~ent invention may be produced in a conventional method and u~u~lly m~y be prepared by m~ns of hlending a mixture of (i) the pharm~ceutically active ingredient and other lngredient~, if nece~ary~ followed by kne~ding, drylng or molding. For t~let~, fu~ther tablç~ting or compres~ion-molding i8 carrled out to gi~e t~let~.
The blendlng of the above phA -ceutlcAlly ~ctlve lS or medicin~l ingrediont~ wl~h ~he r~w mate~ial~ for the prepAr~tlons in do~a~e form~ c~n ~e c~r~ied out by ~ny of the t:onventlon~ in~ technique~ such ~rl mlxlng, kne~ding An~ ~o on. Spec~-flcally, Vertlc~l Granul~tor GV10 (manufac~ure~ by Powr~x Corp.), Universal ~n~-~r ~manufactured by ~ata Iron Works Co., Ltd.) ~n~
fluldlzed bed granulator FD-5S ~manuf~tured by Powrex Corp.~, for ln~t~nce, ~an be employed.
~ he ~l~nd of th~ ph~rm~ceu~ically active ingredlents and the r~w mate~ for ~he prepa~t1on~
ln dos~ge fonno may be directly tablette~, but ~t i8 us~all~ ~ub~ected to kne~ding prior to tablQtting.
The ~ i~g op8ration~ of th~ ~lend containing water can bo carrled out by th~ routine method commonly ~ed ln the art. For example, the devices mentlone~
her~in~efore for the blending of the pharm~o~utlcally activ~ or me~icinal in~redlents wlth the othe~
~ngr~dlento a~ th~ raw ~st~rla~ c~n be utillzed. The drying operation c~n ~e ~rrled out by ~ny of the technLques u~d commonly in the art, ~uch aR v~cuum drying, freeze-drying, spont~neou~ drying, fluidi~e~-bed drying, ~nd ~ on.
'97~10~21~ l9~ ;TA~EDA PATENTS OSAKA Fetherst~n ; 8163006601;#16/27 .
The table~ting or eo~pre~sion-moldlng f~r t~blet~
can be carri~ out uslng ~n equipment çommonly use~ in the gran~lation and compr~sion-molding of t~let~.
~or ex~mple, a single-punch ~s~letting machine ~Kikusui Seisaku~ho~ o~ a rotary type table~ting machine (Kiku~ui S~ ku~ho) can ~e employed. The molding pre~re i~ gener~lly ~bo~ 0.5-3 tDn/cm~.
The ~olid phar~ceutical prepa~tion~, especi~lly the ~ucc~l dl~oLution type tablet~, of th~ pre~ent lnvention thu~ obtalned h~ve fast di~integrabll~ty ~nd di~olubll~ty in the o~al cav~ty.
That is, ~he b~cal di~olution time of the ~ucc~l dissolution typo t~blet of the present ~ nvention t~he time for healthy male adults to complete di~olution ~y lS ~uc~ aliva) 1~ u~ually a~out 0.1-1.0 mln~e~, p~efera~ly ~bout 0.1-0. 8 mlnute~, more prefer~bly about 0.1-0.5 minute~. Th~ h~rdne~ of each tabl~t (mea~ured with a ta~le~ h~dne~ te~ter) 1~ u8u~11y about 2-lS
k~, profer~bly about 3-10 kg.
So~ld Pharm~ceutical Prep~r~tion ~ac~rolln~ of th~ Inven~
The pre~en~ inventlon r~lstes t~ a solld S pharm~ceu~ic~l pr~paration, esp~cially ~ buc~l di~olution type ~olid prep~ration hAvlng ch~racterist~cs of fAst dlsintegr~tion or di~solutlon in the or~l cavlty even witho~t w~ter.
Generally, ~olld ph~rm~ceutlcal prop~ratlonR ~uch ~Y ta~let~ ~re de~lgned ~o th~t afte~ thoy ~re or~lly ~dminl~tored, they disintegratè or dis~olve $n the dige~ive org~n~ ~nd the rhA~ceut~cally ~ctive ingredients ~re ~beoxbed. Accordlngly, f~st d~integrat$on or dl~olution ln the or~l c~vl~y ie no~
a ~ommon design feature.
How~ver, $n ~ccordance with the incr~ae ln the aged population and ch~nge ln life ~tyle~, there ha~
b~n a nee~ for developmont of buccal di~aolutlon type ~oli~ prep~r~tion~ whlch ~n be, lf necessary, 2C admini~tered readily even without ~ater, by aged people and children anywhere or ~nytime, ~aintalning the convenl~nce typ1c~lly a~orded ~y ph~r~ceutic~l ~abl~t~.
A~ th~ t~hnlque for prod~cing prepa~tion~ ~hich 2s ~ickly di~ntegra~e-or dlssolve in the or~l CAvity, horetofo~b, there hn~ been pr~posed ~ metho~ for produclng preparation~ by dis~olving or su~pend~ng pharma~eutlc~l or medicinal ingredlent~ in ~n ~queo~
~olvent, filling ~he re~ultant ~olution o~ su~pension ln~o ~ pocket molded ~eforeh~nd ln ~ bllR~rp~ck ~nd r~duclng wa~er content from ~h~ ~olu~ion by f~eeze-drying or v~cuum ~ryin~ [usp 4371516~Examined Jap~nese Patent Applic~tlon Publlcs~ion ~okoku) No. 62~1~87)-50445), ~/o 93~12769)(Publication of Tr~n~lations o~ ~.
International P~tent Applic~tlon. No. 5-812?6~)]. This metho~, howe~or, ha~ problem~ in tha~ it take~ time for 97~10~21~ 19~00~;TAXE~A PATENTS OSAKA FetherstAn ; 8163006601;# 5/27 m~nufacturing ~nd in that the ol:~tained product~ h8ve in~ufflcient ~trength and thus are ~ifficul~ ~o handle.
Thero is known another method in whlch ~ mixture of phe -ceuti~ally ~ctlve ingrediont wlth ~ low 5 moldBbillty 8AC~haride i8 g~nul~ted with a hîgh molda~ y sac~h~ride added thexeto ~EPA 745382, (Public~Lon of 'rrzln~lat~ on~ o~ In~ernation~l Patent AppllcA~cion No. 7-8203B0 (WO 95t203~0) ) ] . The product obtained by thi ~ method h~s ~uch hArdne~ that the do~age form re~in~ w~thout ~eing dlslntegr~ted ~n the course of di~trlbutlon, whlle the method has a pr~lem ~hAt t~bletting i~ not e~sy, a~ is of~en th~ case with high molds~ility ~ccharide~, be~au~e t~bletting i8 ~arrie~ out with ~ower pre~sure. Also the product~
lS ha~e an ~dditional d~fect that they le~ve ~ problem ~o b~ ~olved in term~ of buccal f~gt dislntegration and dio~olution. On the other hand, there have been made ~tudl~s of ~ucc~l dl~olution preparation~ produced by wetting molding. But, 1n qeneral, t~blet~ hAving fast di~integr~tion o~ di~solution h~ve dçfect~ of l~ç~ ln ~trength.
F~om the foregolng view-polnt, there h~oe ~een a need or dem~nd for d~velopment of prep~r~tion~ which exhi~lt excellen~ buccal di~integration and dissolution ~5 and al~o an ~pprop~late ~trength such that the prep~ration~ never di~inte~r~te or ~uffer dam~ge ln the cour~e of the production ~ep~ ~r dlstributlon ~t~ges.
J~panese Patent Appllcations Laid-open No~ 2~B627, 1-26862~ ~n~ 8-2703~ de~cri~ n pha~ceu~lc~l prep~ra~lon or compo~i~ion conta$ning erythritol, but fail to de~cribe ln~r~buccal ~ olutlon type prepar~tion~.
Th~ ln~r~ntlon provideb ~ol~d ph~rmace-utlcal p~ep~rat$on~ whl~h c~n be re~dily adminiEtered even withou~ w~ter, e~pecially ~olid ph~m~ceutlcal prep~r~tions wh~ch qulck~y disinteg~ate and ~ ol~e in '97~10~21~ 19~00~;TAKEDA PATENTS OSAKA Fetherst~n ; 8163006601;# 6/27 the oral cavlty.
Summ~Jy of the Irlvent1n~
A~ ~ re~ult of inten~1~e ~tudles and r~sear~hes, the pre~ent inventors found ~hat the prep~ration~
compr~i8~ng th~ p~rtlcul~r thr~e ln~redient~, erythritol, cry~talltno ~ellulose ~nd ~ di~lntegrant, in addit~on to a ph~rmaceutl~lly act~e or medicinal ingred~ent, have characte iEtiC~ of fa~t dislnteqr~t~ng andJor di~solvlng in the oral cav$ty, foll~wed by furt~er ~tudie~, which wa~ led to complet~on of the pre~en~ inventlon.
~ hat i~, thls lnvention rel~to~ to ~1) a ~olid pharmace~tical prep~ratlon ~omprislng (i) ~
pharm~coutically ~ctlve ingredlent, (ii) erythritol, ~iil) cry~talllne cellulose ~nd (iv) a di~n~gr~nt;
~2) the solid pharmaceutlcal pr~paratiOn in ( 1 ) ~ whlch 18 capable of buc~al di~integra~lon or dl~olutlon; (3) the ~olid phP~---seutlcal preparation in ~1), which fu~ther comprl~e~ mannitol; ~4) the solld phanm~ceu~ic~l prep~r~tlon in ~1), whorein the di~integrAnt 1~ c ~_~o~$done; (5) the ~oltd pha~m~ceutl~l prepar~tion in (1), wherein crythritol 18 ~ontained ln ~ proportion of S-90 part~ by we1ght, Z5 b~ed on 100 part~ by weight of the sol~d phArm~ceutical preparatlon; ~6) ~he ~olid pharmaceutical prep~rat~on in (lj, wherein the cry~tAilin~ cellulo~e 1~ ~ont~lned in a proportlon of 3-50 pnrts by weight, ~as~d on 100 parts by we~ht of the s~lld ph~rmaceu~ical p~ep~ratLon; 171 th~ ~olid pharm~c~uti~l p~ep~ratlon in (1), wherein the dl~integ~snt is contained in ~ proportion of 1-10 part~
by ~e~ ght, ba~ed on the ~olid pharmaceutical prep~ration; (8) the ~olid pharmA~utlcal prepa~tlon 3S ln (1), wherein the in~redientR, (i) a pharmaceut~cally aotive ingredient, (ii) erythritol, ~iii) cry~talline '9~10~21~ 19~00~;TAKEDA PATENTS OSAKA Fetherst~n ; 8163006601;# 7/27 cell~los~ and (iv) a di~integrant, ~re unlformly mixed, pre~e~bly ~hroughout the prepa~tion; (9) the ~olid phsrInacoutical prep~ration in (1), which iY a tablet;
(10) a sol~d pharma~eutlcal prepar~tion ~apablo of buccal disintegr~tion or di~solut$on, which comprises 0.3-S0 p~rt~ by welght of (1) a ph~r~eutlcally Actlve ingredient, 50-~0 par~ by weight of (il) erythri~ol, AnCl 5-~0 p~ts ~y ~eight of ~ c~yst~llino cellulo~o and 3-7 part~ ~y weight of (iv~ a disintegr~nt; (11) the ~olid pharmaceutical preparatlon in (1), wherein the ph~rmaceutlcally actlve $ngred~ent i~ ~n antldinics o~ 8 drug ~o~ klneto~is or ~otion sl~ne~ 12) a metho~ of improvinq buccal ~ieintegr~tion or ~i~solution of ~ ~olid pharmAceutical preparation cont~inlng 11 ? A phA ~utically active lngredient, whlch compr~se~ lncorpor~tln~ (ii) ~ythritol, (i~i) crystalllne collulo~e ~nd ~iv) ~ dlsln~egr~nt ln combinatlon in the ~o~ld ph~rmac~utic~l prepAr~tion;
~13) u~e of a combin~tlon of (L$) erythrltol, tlli) cry~Alllne cellul4s~ ~nd (iv) ~ dl~integr~n~ fo~ ~he production of ~ ~olid phA-~-~ceu~lcal pxeparation comprl~ing (i) ~ ph~m~ceut$c~11y aCtiv~ i~ ent, with imp~oved bucc~l di8integ~blllty ~nd/or di~olubil~ty; ~14) u~e of ~ composi~lon comp~i~lng ~i~
a ph~- ~eut$cslly activa 1ngI~edient, (~i) erythritol, (il$) crystalllne ~ellulos~ and ~iv) a ~i~integrant for the production of a ~olld ~ Aceutical preparation impr~ved with bucc~l d$sintegra~illty and~o~
di~olu~ility; (15) a method of inhlbiting or treating ~ di~e~e of ~ su~e~t ln n~ed th~reof, which comprl~e~
~dmlni~ter~ng to the subject an effect~ve ~mount of (1) a pharm~ceuti~lly ~tive ingrediont for th~ di~e~e as ~ ~olid ph~lrmaceut~c~l pr~par~i~n ~ont~inlng ~ii) erythr~ol, (iii) cry~t~lline ~ellulo~e ~nd ~iv~ a 3S dl~integrant ln a~ditlon to t~e pharmaceutiç~lly ~ctive ingredi~nt (1~, with improved buccal dl~integrabllity '91~10~21~ 19~00~:TAKEDA PATENT~ OSAKA Feth~rst~n ; 8163006601;# 8/27 ~nd/or di~olu~ility; [1~) a method of m~king a ~o~id ph~rm~ce~tic~l prep~ration, whlch comprlse~ bl~nding a ~ixture of (1) a ph~rmaceutlcally ~ctiv~ lng~edient, ~ii) orythritol, (iil) cry~talllne coll~lo~e and ~iv) disin~egrant, ~nd produ~ing the ~olid pharmaceutical preparatlon from the mixture; an~ (17) th~ metho~
according to t16), wheroin the sol$d preparatlon di~olves completely in ~olely buc~l s~liva within 1 minut~ of admini~tr~tlon to a patient.
D~tA1 1P~ C~1~t;0rl of ~ Inve~ttn~
The ph~rmace~tic~lly ac~ive or me~lcinal tng~edlent-to b~ u~ed in the preRent invention m~y be in ~ny optional form, ~or example, a ~olid, powder or gr~nular, cr~stalline, oily ox ~o~uti~n form.
There 1B no limitation to ~he ph~rmAceutic~lly ~ctive lngredlen~ to be used. As the ph~rmaceutic~lly ~ctlve ingredi~nt, for ~x~mple, the~e may be mentioned one or more ~eM~rs ~ele~ted from ~he group con~i~tlng of nouri~hlng ~nd heal~h-promoting ~gents, anti-pyretlc-analge~ic-~ntlin~l~mmatory agents, ~ an~ip~ychotic drug~, anttAnyiety drug~, ~ntidepressant~, hypnotic-~edative~, ~pa~molytic~, gastrolnte~tinal function conditioning nyent~, antacld~, ~nt1tu~ive-exp~c~orant~, dental buccal drug~, an~lhi~tamines, cardiotonlcR, ~ntlarrhythml~
drugs, d~ure~ic~, antihypertensive drug~, v~ocon~trlctor~, co~on~ry vasodlla~o~, peripheral v~odilators, cholagogue~, antibiotlcs, chemother8peutlc ~rug~, ~ntidiabetic agent~, dru~s for ~teoporo~is, skoletal muscle rel~xant~, ant~dinic~ o~
dru~ for ~in~to~i~ or motion pickness and the llke.
~ x~mples of th~ nou~i~hinq and ~al~h-promoting agent~ include vitAmin~ such a~ vitamln A and lt~
deriv~tive~, vl~min D and its de~ivatl~eR, vitamin E
and it~ deriv~tives (d-a-tocopherol aceta~e etc~)~
'97~10~21~ 19~00~;TAKEDA PATENT~ OSAKA FetherstDn ; 8163006601;# 9/27 vl~Min ~1 and its der~va~l~e~ ~di~enzoylthi~m~ne, fur~ul~iamine hydro~hloride e~.), vitamin ~z and it~
~erivatlves (riboflAvin butyrate etc.), vitamln Bh ~nd lt~ deriva~l~es (pyr1dox$n~ hydrochloride etc.~, vit~mln C and its de~iv~tlvos (asco~bic ~cid, ~odium ~-~corba~e etc.), vi~amin ~1~ and lt~ derivatlve~
~hydroxocobal~mln acet~te etc.), etc., a~ w~ll a~
mlner~ls such ~ calcium, magne~lu~ And iron, prote~n8, amino ac$d~, oligo~acch~ride~, crud~ drug~ ~nd the like. Example~ of th~ ~ntlpyretic-analgesic-ant~in~l~mmato~y ~gent~ include, asplrin, acet~minophen, ~thenz~mi~e, i~uprofen, diphen~y~r~mlne hy~rochlorid~, dL-chlorphenlramlne m~le~te, dihydrocod~ine pho~phate, no~capine, methylephedrlne hydrochloride, phenylpropanolamlne hydrochlor5~e, caffeine, anhy~rous caffeine, ~erratiopeptldase, ly~ozym~ chloride, tolfenamic ~c~d, mefenamic acid, diclofenac ~odLum, flufenamlc ac~d, ~a~lcylamide, am~nopyrlne, ketoprofen, ~ndometh~cln, bucolome, pentazoc!ine and ffo on.
Ex~mples of the an~ip~ychotlc ~l~ug9 lnclud~
chlorpromazine, re~erpln~ and 80 on. Example~ of the anti~nxlety drug~ include chlordl~2epoxide, diazepam, etc. Example~ of the an~$depre~snt~ Lnclud~
2S lmipramine~ maprotillne, ~mphetaminc and ~o on.
Example~ of the hypnotic-~ed~tives include e~t~zol~m, nitrazep~m, di~z~p~m, ph~nobarhital sodium and ~o on.
~5xamples of the sp~3mol~tic~ lncludo ~copol~mlne ~ydro~romide, diphenh~mlne hydrochloride, p~p~verine hydrochlorlde And 90 on.
Example~ of the gastrointestinal functlon condlt1 onlng agen~ include stomachic-d1gestlve~ ~uçh ~B d~a8te~Q, anc:charated pop~n, ~copoliu ~xtr~ct, lipa~e AP, cinnamon oil, etc., lntest~n~l func~ion con~oll$ng dru~ ~uch ~ h~r~rine çhloride, re~istant lactic ~cid b~terlu~, Lacto~Acillu~ ~ifidu~ and ~o on.
'97~10~21~ 19~00~;TAKEDA PATENTS OSAKA Fetherst~n 8163006601:#10/27 ~xample~ of the ant~ci~ include magne~ium c~bonate, ~odium hydrogen carbonate, magne~ium alum~nometasillc~te, synthet~c hydrotalc$te, prec~pit~ted c~l~ium carbon~te, magn~sium oxide and ~o on.
Exnmples of the anti~u~ive-expeotorAnt~ lnclude chlopera~ti.no hydrochlori~e, d~xtromethorph~n hydrobromide, t~eophylline, pota~ium guaiacol~ulfonate-, gu~ifenesin etc. Example~ of the dental bucc~l drug~ lnclud~ o~ytetracycline, trlamcinolon~ ac~tonl~, ohlorhexldine hydrochloride, lidoc~ine ~nd ~o on.
Example~ of the ~ntlhl~tam~n~ incl~de diphenhy~r~mlne hy~rochlorlde, promethazlne, i~othipendyl ~t~hlorlde, dl-chlorphenir~mlen malo~to, etc. Exa~ple~ of the cardiotonlc~ include etllefrine hydrochlorid~ J~nd 80 on. Exalnple~ of the anti~rryhythmic drug~ include pro~aln~mide hydrochlorldo, propr~nolol hydrochlor~de, pindolol snd 90 on. ExampleE~ of the d~uretic~ include i~o~or~ide, furosemide and 80 on. Ex~mple~ of ~he ~ntihyperten~lve dru~ include delaprll hydrochloro~ido, ~aptoprll, hexa~othonlum bromlde, hydrala~ine hydrochlorlde, l~bet~lol hy~rochlorlde, methyldop~ and the l~ke.
Ex~mple~ of the ~80con~trictor~ ~nclude phenylephrine hydrochlo~id~, etc. Example~ of the coronary v~sodil~tora include car~o~romen hydrochlorlde, mol~ldomine, verap~mil hydrochloride ~nd ~o on. Ex~mplç~ of the peripheral vnsodllator~ lnclude cinnar~zino and ~o an. ~xample~ of the eholagogues includq dehydrochoLic ~cld, treplbut~no and Ra on.
~xample~ of the antibiotlcs in~lude c~phe~, penem~ and ~rbapene~ uch a-s cef~lexin, ~moxLc~llin, p$vmecillin~m hyd~ochlorido, cefotism dlhyd~ochlorlde etc. Examples of the chemothe~apeutl~ ~rug~ lnolude ~lfamethl~ol~, thiazo~ulfone and ~o on. Examples of '97~10~21~ l9~00~;TAKEDA PATENTS O~AKA Fetherst~n ; 8163006601;#11/27 the an~idi~bet~c ag~nt~ inc~ude tol~ut~mi~e, vogllbo~e and ~o on. Ex~mple~ of the drug~ for o~teoporo~ls include ip~iflavone ~nd 80 on. Examp~e8 of the skeletal ~u~cle rel~xant~ in~lude methoc~rb~mol and ~o on. Exa~ple~ of the Antidin$c~ or drug~ for kinetosi~
or motion sickne~, i.e. ~ntimotlon ~icknes~ drug, include meclizine hy~rochlorldç, di~enphydrin~te and ~o on.
The ph~rmac~u~ic~l~y ac~i~e or medicin~l lngredient may l~o ~iluted w~ch a dlluent which 18 u~ed generally in th~ pharmaceutical or food indu~try. At le~t one o~ the pharm~ceutlcally ~otive lng~edien~s may ~e ln ~n ol~y form, Among ~uch pharm~ceuti~lly active ingredients, preferred ex~mple~ for purpo~ of the p~esent invention a~e vit~mln~, crude drugs, antip~rotic-analgesic-an~iinflamm~tory Agent~, ~ntLanxioty drugs, hypnotic-sedative ~gent~, gas~rointestlnal func~ion conditioning agent~, anti~u~81~e-e~pec~or~nt~, ant~hyperten~1ve drugs, antidlabetic~, drl~gs for o~teoporo~i~, skeletal muocle rel~xant~ and antidlnlc~
Or drugs ~or kineto~l~ or motlon sickneR~.
Espec$~11y prefer~le ac~ive ingredientR for t~e ~:pr~sent inventlon ~re~an~idinlc~ o~ drugs for klnetosi~
or motion sit:kness in that suc~h drug~ ~re often r~q~red to be adminietered without water for prev~ntlon or tre~tment of ~ine~06i~ or motion ~icknos~.
The ~ol$d pharm~ceutical prepar~tions of thç
present inventlon cont~in the ~bove-mentioned ph~rmaceutic~lly activ~ or me~icinal ingredi~nt~
u~ually in a propo~tion of about O.05-700 by we1~ht, pr~afer~bly about O.1-50~ hy ~eight, more prefer~bly 0.3-30~ by welght.
Eryth~itol to be u~ed ~ one of the ra~ materiAls for the prep~ra~ion~ of t~e pre~ent inventlon i~ a kind 97~10~21~ 19~00~;TAKEDA PATENTS OSAKA Fetherst~n ; 8163006601;#12/27 of ~ugar ~lcohol and ia in ganer~l produced by ferm~ntation wl~h yea~t~ u~lng gluco~e a~ the ~t~rting m~teri~l. U~u~lly, ery~h~itul product~ h~v$ng a pA~ticle size capAbl~ of p~s~ing throu~h a 50 m~h 5 8ieve ~re used. These pro~uCt~ ar~ available on the m~r~et, and examples of ~uch produc~ include ~rythritol ~nufactu~ed by Nikken Chemical Co., ~td.
Erythrit~l is lncorpor~ted ln a proportlon of About S-90 part~ ~y ~eight, prefe~ly About 10-80 t 0 p~rts by weight, more preferably ~bout 50-80 p~rts by wç~ght, ~ed on 100 p~t~ ~y weigh~ of the ~olid pharn~ceutic~l prepa~ation.
The preparat$on of the pre~ent invention prefçr~bly compri~e~ cry~talline çellulose, whlch iq al~o c~lled ~icrocry~talline cellulo~e, and typically ~uch c:rystalline cellulo~e tha~ i8 produced by ~rtially depolymerizin~ ~-cellulo~e ~nd purifying the resultant polymer can be u~ed.
Ex~mple~ of the cry~talllno c~llulo~o to be u~ed 1n the pre~ent lnvention lnclude products o~ Yariouo gr~de such ~-CEOLUS KG801, ~vicel PH101, av~cel PH102, avicel PH301, avicel PH302, ~vicel RC S91 (crystall1ne c:~llulase c~rmelloele ~odlum) ~nd 80 on. A~ the crys~alline cellulo~e, one ~pecle~ m~y be used oingly or altern~tively two o~ more ~pe~ie~ may be used in ~omblnation. Moro pre~e~red ~xample~ of the crystalline cellulo~e ~re CEOLUS gG8nl which iB calln~
~vicel of hlgh comprossi~illty. ~hesa r~w materl~ls are ~vall~ble on tho market, ~hlch ~re exempllfied by ~ho pro~ts manufac~ur~d ~y A~shi Chemic~l Co., Ltd.
C~ry9t-~lllne cellulo~e i8 ~ontalned in 1l propo~tion of about 3-50 parts by weight, prefor~bly ~bout 5-40 par~B by wei~ht, ~re prefnr~bly ~hout 5-20 part~ by welght, ~ase~ on 100 p~rts by wolgh~ of the solid E'll'IA AC!~UtiC~,l prepArRtion-As the diainteg~nts to ~e used fo~ the pre~qnt '97~10~21~ 19~00~;TAKEDA PATENTS OSAKA FetherstAn : ~163006601;#13/27 1~1 ~ inven~lon, unle~ the ob~ct of ~he invontion ~8 interfored wlth, ~ny d~integrant~ ~hi~ are ~n common u~e in the pharm2~eutical f1lod. Example~ of most pr~fe-r~d dl~i~t~gr~nte i~lude tho~e known a~ super dln~n~egrant su~:h ~ cro~povidone ~ISP Inc., B~SF), croscarmello~, cl~-A~nmollo~e ~odium (FMc-A~ah$
C~emical ~o., Ltd.), car~ellose c~lcium [~otoku Chemicsl ~Yakuhin) ] . ~ther prefe~d example~ of dl~lntegran~s inclu~e carboxymethyl~t~rch ~odium ~at~utani ~hemic~l ~o., Ltd.l, low ~ubstituted hyd~oAyy ~yl cell~lo~e (Sh~n-Et~u ¢hemiçal Co., Ltd.), ~orn ~tarch ~nd ~o on. The~e dislnte~rantb can be u~ed ~ingly or two Or more ~pecie~ c:an be u~ed in combin~tion. For ex~mp~e, prefera~ly, cro~povldone m~y be used ~ingly or in combinstion with other dlsintegran~. Here, 80 ~ro~po~idone, any c~o~-linked homopolymer cslled 1-ethenyl-2-pyrrol~inone homopolymer may be used, ~nd usually cro~po~i~one h~ving ~ molecul~r ~eight o~ ~,000,~0 o~ more.
Sp~cl~i~ example~ of cro~po~idone ava~l~blo ~ n th~
m~rke~ inclu~e ~ross-lln~e~ povidone, Kollidon C~, Polyp~a~done Xh, Polypla~done X~-10, INF-10 (manu~actured by ISP), p~lyvlnylpoly~ olidone, PVPP
~nd l-vinyl-~-py~olid$none ho~opolymer.
These ~:lisintegr~nts ~r~ u~uslly lnco~por~ted in proportion of a~out 1-15 p~ts by welght, prefer~bly About 1-10 p~rt~ ~y welght, more prefer~bly 4bout 3-7 p~rts by wel~t~ ba~ed on 100 p~t~ by welght of the Jolld pharm~ceutic~l prep~rAtlon.
. In the present invention, in ~dd~tion to the a~ove-m~ntioned ingre~ientn, ~annltol c~n b~ furth~r ad~ed. Mannitol ~vail~ble on t~e market can be employed, an~ ~uch m~nnltol 1B exempllfied ~y the prod~ct m~nufactured by Tow~ Ch~mLcal ~a~ei~ Co., Ltd.
3S U~u~lly, mannitol L~ employed wlth ~ partlclo ~iz~
capable of pa~ing th~eugh ~ lso-me~h ~ieve.
'97~10~21~ l9~00~;TA~EDA PATENTS ~AKA ~eth~rstAn 8163006601;#14~27 ~he ~olld phAr-"~ceutlc~l prepara~ion~ of the pr~sent t nvention are u~eful especially ~ buccal ~is~o~ution type solid prep~rations, which, t~lough in a ~o}ld fonm, ~f~e~ or~lly admini~tered, intr~bucc~lly dl~olve or di~integr~te withou~ being ~wnllowed. As the do~ge form of the ~oli~ prepara~ions, there may be generAlly mentioned granule~, ta~le~s and the like.
More prefe~le do~age forms of the ~olicl prepar~tiOns of the present inven~ion ~re t~let~. Such t~letB are characterized in that they ha~ ~pp~opr1ate h~rdneB~.
Unle~s the ob~ect of the invention 1 B intQrfe~ed with, the abov~ -nt~oned preparation of ~he pre~en~
inventlon m~y furthor cont~in ~ variety of addltivee ~hich ar~ commonly employe~ in the m~nuf~cture of prepar~tion~ ln qeneral do~g~ fo~m~.
The addi~lves mentioned ~ove ~nclude, among . others, binder~, ~clds, fo21snlng ~en~, altif~clal ~weeteners, flavorants, lubrlcant~, colorAnts ~nd ~o on .
Example~ of the binder~ ~nclude hydroxyprop~l~ellulo8e~ hydr~y~ u~ylmethylcellulo~e~
a-starch, polyvlnylpy~r~lidone, gum arAbic powdQr, gela~in, pullulan ~nd the like.
Ex~nple~ of the aclds includo citrlc acld, t~rtari~ ~cid, ~nd Ine.lic ~cid ~nd 80 on. Ex~mple~ ~f t~e foamlng agent~ ln~lude ~od$u~ hydrogen ca~bonat~
and 80 on. Ex~mplee of t~o nrt~fioial ~weetener~
~nclude ~accharin ~odium, dipot~lum glycyrr~izinate, ~part~me, ~tevia, th~umatln and so on. Ex~mple~ of thc flavorantR lnclucle lemon, lemon lime, orAnge, m~nthol and the li~e. Ex~mple~ of the lu~rlc~nt~
lnclud~ magnesium ~te~ate, eucro~e fatty ncld e~ter, p~ly~t~ylenegl~col, t~lc, ste~ric a~id ~nd th~ li~.
Example~ of the colorant~ include v~riou8 food color8nt~ e.g. FD~C Yellow No. 5, F~&C ~ED No.2, Fn~c Blue No. 2, e~c., foo~ lake~, red iron ox~de ~n~ ~o on.
'97~.0~21~ 19~00~;TAKEDA PATENTS OSAKA Fetherst~n 8163006601;#15/27 .
Preferably, the 801i d pharmac~uticsl preparatlon of the pr~ent ~nv~ntion ~ompri~es the above-men~ioned ingredlents homogeneou~l~ or uniformly In other wordR, ~ho ingredlent~ ~ro p~efer~ly intimately ~nd uniformly mixed throughout tho prep~ation.
The ~olid pharmacoutical preparation ~ccordlng ~o the pre~ent invention may be produced in a conventional method and u~u~lly m~y be prepared by m~ns of hlending a mixture of (i) the pharm~ceutically active ingredient and other lngredient~, if nece~ary~ followed by kne~ding, drylng or molding. For t~let~, fu~ther tablç~ting or compres~ion-molding i8 carrled out to gi~e t~let~.
The blendlng of the above phA -ceutlcAlly ~ctlve lS or medicin~l ingrediont~ wl~h ~he r~w mate~ial~ for the prepAr~tlons in do~a~e form~ c~n ~e c~r~ied out by ~ny of the t:onventlon~ in~ technique~ such ~rl mlxlng, kne~ding An~ ~o on. Spec~-flcally, Vertlc~l Granul~tor GV10 (manufac~ure~ by Powr~x Corp.), Universal ~n~-~r ~manufactured by ~ata Iron Works Co., Ltd.) ~n~
fluldlzed bed granulator FD-5S ~manuf~tured by Powrex Corp.~, for ln~t~nce, ~an be employed.
~ he ~l~nd of th~ ph~rm~ceu~ically active ingredlents and the r~w mate~ for ~he prepa~t1on~
ln dos~ge fonno may be directly tablette~, but ~t i8 us~all~ ~ub~ected to kne~ding prior to tablQtting.
The ~ i~g op8ration~ of th~ ~lend containing water can bo carrled out by th~ routine method commonly ~ed ln the art. For example, the devices mentlone~
her~in~efore for the blending of the pharm~o~utlcally activ~ or me~icinal in~redlents wlth the othe~
~ngr~dlento a~ th~ raw ~st~rla~ c~n be utillzed. The drying operation c~n ~e ~rrled out by ~ny of the technLques u~d commonly in the art, ~uch aR v~cuum drying, freeze-drying, spont~neou~ drying, fluidi~e~-bed drying, ~nd ~ on.
'97~10~21~ l9~ ;TA~EDA PATENTS OSAKA Fetherst~n ; 8163006601;#16/27 .
The table~ting or eo~pre~sion-moldlng f~r t~blet~
can be carri~ out uslng ~n equipment çommonly use~ in the gran~lation and compr~sion-molding of t~let~.
~or ex~mple, a single-punch ~s~letting machine ~Kikusui Seisaku~ho~ o~ a rotary type table~ting machine (Kiku~ui S~ ku~ho) can ~e employed. The molding pre~re i~ gener~lly ~bo~ 0.5-3 tDn/cm~.
The ~olid phar~ceutical prepa~tion~, especi~lly the ~ucc~l dl~oLution type tablet~, of th~ pre~ent lnvention thu~ obtalned h~ve fast di~integrabll~ty ~nd di~olubll~ty in the o~al cav~ty.
That is, ~he b~cal di~olution time of the ~ucc~l dissolution typo t~blet of the present ~ nvention t~he time for healthy male adults to complete di~olution ~y lS ~uc~ aliva) 1~ u~ually a~out 0.1-1.0 mln~e~, p~efera~ly ~bout 0.1-0. 8 mlnute~, more prefer~bly about 0.1-0.5 minute~. Th~ h~rdne~ of each tabl~t (mea~ured with a ta~le~ h~dne~ te~ter) 1~ u8u~11y about 2-lS
k~, profer~bly about 3-10 kg.
2~ Therefor~, the bucc~l di~olution type t~blets of the prosent lnvention c~n-be u~ed for ~he therapy or prophyl~x1q of variou~ es ~u~t a~ ~he conventional preparation~ con~aining ~he s~me pharmaceutically ~ctlve ingredient but with 8n increa~ed e~e o$ ~dmlnlstr~tion or inge~tlon by aged persona and ehildren, ~nd also ~s ~afe preparations in ~e of emergency for gener~l ~dult~. The table~ Of the invention f~rther fea~ureE a long ~hel~-life. The ~olid pharm~ceut~cal prepe.ration c~n be in general 30 ~dmln$~tered in the s~me -nne~ as convention~l pre~p~rationEI ln clo~ge form~s for oral adnlini~atration and more ~s~ly even without wate~.
Th~t i2~, tl~e elol~d ph~ ---outi~l p~eparat~ OA h~
low toxcity and i~ ~a~y to take and the~efore c~n be safely ~dminl~t~red to humans r~nging from chlldr~n to ~ged peopl~. While depending on th~ ~ctive lngredlent, 97~10~21~ 19~00~:TAKE~A PATENT~ OSAKA Fetherston ; 8163006601:#17/27 ~everity and ~ge of the su~oct ~nd so on, the do~age varles, tho do~age i8 in general ~he B~me ~9 the conventional prep~rAtion~ of the re~pective pharmaceu~i~ally ~ctive ingredients. For ex~mple, fo~
S ~he preparation of meclizine hydrochlo~ide, the ~ily do~ge fo~ adult 1B a~out 1-100 ~g, preferably about 10-75 mg a~ the ~ctive ~n~edient. Al~o, the da$1y do~ge fol~ adult of 400pol~m1ne hydrobromide iR a~ut 0.01-1 mg, proferably about 0.05-0.5 mg.
The following example~ ~re further llluotr~tlve but by no ~e~n~ lim~tat~ve of the prç~ent inventlon.
~S~
~5 The physi~al p~opertle~ of the tablets propared in the Examples ~nd Comparat~ve Ex~mplea werQ determln~
by the following te~ ~ethod~.
tl) H~rdn~t~ tes~
Th~ hardne~ of each tA~let wa~ ~ea~ured with ~
tablet h~rdness te~tor ~m~nufactu~ed by S~hleuniger).
The te t wa~ performed ln 3-10 run~ and the mean of the ~ee~urement re~ t~ w~re Rhown..
(~) Buccal di~801utlon time Th~ tlme for a m~le adult to complete 2S diEln~gr~tlon or dl~olutlon only by sali~a in the or~l cavity w~ mo~ured.
Exa~pl~o 1-2 ~nd Compar~tlvQ Ex~mple~ 1-3 The composition~ of the preparatlono of EX~mples 1 ~nd 2 of the pr~ent inven~ton a~d tho~e of Compa~ative ~xample~ 1,2 ~nd ~ are shown in Ta~le 1.
A kneading mnchlne t~owrex vertlcAl ~ranu~ator) was charged with m~dicin~l in~redient~, erythrltol ~nufncture~ by Nlkken Chem~çal Co., Ltd.~, m~nnltol ~m~nufactured by Tow~ Chemlcal (~ Co., Ltd.), ~rystallin~ cellulo~e ~manufactur~d by A~hi Chem~c~l 9~10~21~ 19~00~;TAKEDA PATENT~ OSAKA Fetherst~n ; 8163006601;#18/27 }5 Co., Ltd. ) and c~o~povidone (po~yplasdone XL-lO, manufactured by ISP Inc.) in the re~pec~ive ~mount~
$nd~c~ted ~n ~he ~ormula~, ~nd the chargo wa~ kne~ded (at 400 ~pm for 3 minut~) wlth a 50~ ~thanol ~olut~on.
The kn~ d m~8 w~ dr~ed ~nd ~ ~nuted ~ith ~
pow~rmill (with 1.5 ~m screen~. A~t~r ~dditlon of magne~ium ste~te in a p~opo~tion of 0.3~, the gr~nule~ w~re comp~eo3~0n-molded or t~ble~ted u~in~ ~
rotary type tabl~ting mac~lne (m~nufact~red by ~lku~ui Seis~ku~ho Co., Ltd.), with a punch having ~ beveled ed~e, 10 mm ln di~m~ter, at ~ moldlng pre~ure of 1.~
ton/cmZ~ to provide tablet~ e~ch we~ghing 400 mg. The h~rdnes~ ~nd ~uccal diecolution tlm~ of e~h t~let thuE~ o~t~; no~ W~8 mea~ured. ~rhe re~u~ts ~re shown in ~ble 2.
Table 1 FO~DIU1A - E~npl~! Comp~ratlve ~x~mple MRçllzin- S0 gO 50 50 50 h~rochlor~te Scopol~nlne0.2S 0.25 0.25 0.25 O.Z~
hydrobrumlde C~ffelne 40 40 40 40 40 Vlt~mln 36 20 20 20 Z0 20 Erythrltol575.752~4.8 344.9 224.8 284.8 ~Annltol ~ 264.g5 344.85 284.~S 284.95 Lu~ oub~tltutet ~ 120 hy~ruxypropyl-cellulose Clyot~lline120 120 - lZO
c~ lo~
Cro~pc~vldone 40 40 - - -Tot_l 800.0g800. OBaoo . og OOO.O~ eoo.o~
'97~10~21~ 19~00~;TAKEDA PATENTS OSAKA Feth~rst~n ; 8163006601;#19/27 .
Table 2 Phy~lcal ~umple Comp~r~tivQ Ex~ple prop~rty 1 2 1 ~ 3 H~rdneoR ~kg) ~.~ C.2 2.3 5.0 6.2 Bucc~ ZS 115 ~2 140 disool~tion tlme t BeCclhd) .. .
1~
Ex~mples 3-4 and Compar~tl~e Ex~mple 4 In Table 3, the compositlon~ ~re ~hown of tho pr~para~ion~ of ExAmple~ 3 ~n~ 4 of the pr~ent invent~on and ~ preparat$on of Compara~ivo ExAmplq 4 for compar~ son~
Medlclnat ingredlent~, exythritol (manu~tured by Nlkken Chemi~l Co., Ltd.), mannitol ~manufactured by ~ow~ ~a~ei Co., Ltd.), cry~talllne cellulose (manufactured ~y Asahi Chemical Co., Ltd.), 20 cro8povidone ~nuf~ctured by ISP Inc.~ and m~gneBiu~
8t~ara1:e 1. 0~ w~e blcnded in accordanc~ with tho re~pectlve formulns and t~ble~ed by a dirtet tab~etting method wlth ~ rotary type tabletting maehine (m~nuf~ctur~ed by ~Cik~ ul Sei~kusho Co., Ltd.) with A
moldlng punch havlng a beveled edg~, 10 mm in diameter, a~ ~ pr~s~uro 1 . 2 ton/cm2, to prov1do t blet~ e~ch - w0ighing 400 mg. The har~ness ~nd ~ucc~l di~olution t~me of each tablet thus obtain~d was m~a~ured. The re~ult~ ~re ~hown in Ta~le 4.
9~10~21~ 19~00~;TAKEDA PATENTS OSA~A F~therstAn ; 8163006601;#20/2 Table Pnrmul~E~mple 3 Example 4 Ccmp~ratl~
E~mple 4 M~clizlne So 50 50 hJdrochlurld~
Scopol~m~ne O.Z5 0.25 0.25 hy~ro~rom~de ~ff~ne 40 40 40 Yitamln ~6 20 2C . 20 Erythr~tol . 204.gO ZO4.gO ZO4.90 M~nnitol . 204.85 204.85 ZO4.~5 Lo~ sub~titueed _ - 240 hydroxyprop~l~clluloYe Cr~st~ na cellulvse 240 Z40 Cro~pov~done 4O - 40 Cro~c~rmello~e ~otlum - 40 Total 800 ! Og 800.0~ 800.0g ~able 4 .
Phyolc41 E~mple 3 Ex~mpl~ 4 ~ompAr~tlv~
pr~p~rty ~mple 4 ~r~ne~G tkg~ 6.6 5.1 6.9 ~uc~l 33 4S loS
dl~olutlon tlmo ~econd~
Ex~mple 5 Hnc~ ~omparative Example 5 In T~ 5, thero are shown the composit ~ on~ of the preparationQ of Example 5 of the pre~ent invention an~ the prep~ratlon of r- ,~tive Ex~mple S for colnp~rlson .
A f luidl z~d-~ed granulator ~ Powr~x Co ., ~d. LABl~
Th~t i2~, tl~e elol~d ph~ ---outi~l p~eparat~ OA h~
low toxcity and i~ ~a~y to take and the~efore c~n be safely ~dminl~t~red to humans r~nging from chlldr~n to ~ged peopl~. While depending on th~ ~ctive lngredlent, 97~10~21~ 19~00~:TAKE~A PATENT~ OSAKA Fetherston ; 8163006601:#17/27 ~everity and ~ge of the su~oct ~nd so on, the do~age varles, tho do~age i8 in general ~he B~me ~9 the conventional prep~rAtion~ of the re~pective pharmaceu~i~ally ~ctive ingredients. For ex~mple, fo~
S ~he preparation of meclizine hydrochlo~ide, the ~ily do~ge fo~ adult 1B a~out 1-100 ~g, preferably about 10-75 mg a~ the ~ctive ~n~edient. Al~o, the da$1y do~ge fol~ adult of 400pol~m1ne hydrobromide iR a~ut 0.01-1 mg, proferably about 0.05-0.5 mg.
The following example~ ~re further llluotr~tlve but by no ~e~n~ lim~tat~ve of the prç~ent inventlon.
~S~
~5 The physi~al p~opertle~ of the tablets propared in the Examples ~nd Comparat~ve Ex~mplea werQ determln~
by the following te~ ~ethod~.
tl) H~rdn~t~ tes~
Th~ hardne~ of each tA~let wa~ ~ea~ured with ~
tablet h~rdness te~tor ~m~nufactu~ed by S~hleuniger).
The te t wa~ performed ln 3-10 run~ and the mean of the ~ee~urement re~ t~ w~re Rhown..
(~) Buccal di~801utlon time Th~ tlme for a m~le adult to complete 2S diEln~gr~tlon or dl~olutlon only by sali~a in the or~l cavity w~ mo~ured.
Exa~pl~o 1-2 ~nd Compar~tlvQ Ex~mple~ 1-3 The composition~ of the preparatlono of EX~mples 1 ~nd 2 of the pr~ent inven~ton a~d tho~e of Compa~ative ~xample~ 1,2 ~nd ~ are shown in Ta~le 1.
A kneading mnchlne t~owrex vertlcAl ~ranu~ator) was charged with m~dicin~l in~redient~, erythrltol ~nufncture~ by Nlkken Chem~çal Co., Ltd.~, m~nnltol ~m~nufactured by Tow~ Chemlcal (~ Co., Ltd.), ~rystallin~ cellulo~e ~manufactur~d by A~hi Chem~c~l 9~10~21~ 19~00~;TAKEDA PATENT~ OSAKA Fetherst~n ; 8163006601;#18/27 }5 Co., Ltd. ) and c~o~povidone (po~yplasdone XL-lO, manufactured by ISP Inc.) in the re~pec~ive ~mount~
$nd~c~ted ~n ~he ~ormula~, ~nd the chargo wa~ kne~ded (at 400 ~pm for 3 minut~) wlth a 50~ ~thanol ~olut~on.
The kn~ d m~8 w~ dr~ed ~nd ~ ~nuted ~ith ~
pow~rmill (with 1.5 ~m screen~. A~t~r ~dditlon of magne~ium ste~te in a p~opo~tion of 0.3~, the gr~nule~ w~re comp~eo3~0n-molded or t~ble~ted u~in~ ~
rotary type tabl~ting mac~lne (m~nufact~red by ~lku~ui Seis~ku~ho Co., Ltd.), with a punch having ~ beveled ed~e, 10 mm ln di~m~ter, at ~ moldlng pre~ure of 1.~
ton/cmZ~ to provide tablet~ e~ch we~ghing 400 mg. The h~rdnes~ ~nd ~uccal diecolution tlm~ of e~h t~let thuE~ o~t~; no~ W~8 mea~ured. ~rhe re~u~ts ~re shown in ~ble 2.
Table 1 FO~DIU1A - E~npl~! Comp~ratlve ~x~mple MRçllzin- S0 gO 50 50 50 h~rochlor~te Scopol~nlne0.2S 0.25 0.25 0.25 O.Z~
hydrobrumlde C~ffelne 40 40 40 40 40 Vlt~mln 36 20 20 20 Z0 20 Erythrltol575.752~4.8 344.9 224.8 284.8 ~Annltol ~ 264.g5 344.85 284.~S 284.95 Lu~ oub~tltutet ~ 120 hy~ruxypropyl-cellulose Clyot~lline120 120 - lZO
c~ lo~
Cro~pc~vldone 40 40 - - -Tot_l 800.0g800. OBaoo . og OOO.O~ eoo.o~
'97~10~21~ 19~00~;TAKEDA PATENTS OSAKA Feth~rst~n ; 8163006601;#19/27 .
Table 2 Phy~lcal ~umple Comp~r~tivQ Ex~ple prop~rty 1 2 1 ~ 3 H~rdneoR ~kg) ~.~ C.2 2.3 5.0 6.2 Bucc~ ZS 115 ~2 140 disool~tion tlme t BeCclhd) .. .
1~
Ex~mples 3-4 and Compar~tl~e Ex~mple 4 In Table 3, the compositlon~ ~re ~hown of tho pr~para~ion~ of ExAmple~ 3 ~n~ 4 of the pr~ent invent~on and ~ preparat$on of Compara~ivo ExAmplq 4 for compar~ son~
Medlclnat ingredlent~, exythritol (manu~tured by Nlkken Chemi~l Co., Ltd.), mannitol ~manufactured by ~ow~ ~a~ei Co., Ltd.), cry~talllne cellulose (manufactured ~y Asahi Chemical Co., Ltd.), 20 cro8povidone ~nuf~ctured by ISP Inc.~ and m~gneBiu~
8t~ara1:e 1. 0~ w~e blcnded in accordanc~ with tho re~pectlve formulns and t~ble~ed by a dirtet tab~etting method wlth ~ rotary type tabletting maehine (m~nuf~ctur~ed by ~Cik~ ul Sei~kusho Co., Ltd.) with A
moldlng punch havlng a beveled edg~, 10 mm in diameter, a~ ~ pr~s~uro 1 . 2 ton/cm2, to prov1do t blet~ e~ch - w0ighing 400 mg. The har~ness ~nd ~ucc~l di~olution t~me of each tablet thus obtain~d was m~a~ured. The re~ult~ ~re ~hown in Ta~le 4.
9~10~21~ 19~00~;TAKEDA PATENTS OSA~A F~therstAn ; 8163006601;#20/2 Table Pnrmul~E~mple 3 Example 4 Ccmp~ratl~
E~mple 4 M~clizlne So 50 50 hJdrochlurld~
Scopol~m~ne O.Z5 0.25 0.25 hy~ro~rom~de ~ff~ne 40 40 40 Yitamln ~6 20 2C . 20 Erythr~tol . 204.gO ZO4.gO ZO4.90 M~nnitol . 204.85 204.85 ZO4.~5 Lo~ sub~titueed _ - 240 hydroxyprop~l~clluloYe Cr~st~ na cellulvse 240 Z40 Cro~pov~done 4O - 40 Cro~c~rmello~e ~otlum - 40 Total 800 ! Og 800.0~ 800.0g ~able 4 .
Phyolc41 E~mple 3 Ex~mpl~ 4 ~ompAr~tlv~
pr~p~rty ~mple 4 ~r~ne~G tkg~ 6.6 5.1 6.9 ~uc~l 33 4S loS
dl~olutlon tlmo ~econd~
Ex~mple 5 Hnc~ ~omparative Example 5 In T~ 5, thero are shown the composit ~ on~ of the preparationQ of Example 5 of the pre~ent invention an~ the prep~ratlon of r- ,~tive Ex~mple S for colnp~rlson .
A f luidl z~d-~ed granulator ~ Powr~x Co ., ~d. LABl~
3~ wa~ ch~ged w~th the medLcin~l ing~edient~, erythritol (m~nufactured by Nikken Chemical Co., Ltd.), cry~talline ~ellulose (~nufactured ~y ~hi Chem1cal '97~10~21~ 19~00~;TAKEDA PATEMTS OSAKA Fetherst~n ; 8163006601;#21/27 Co., Ltd.), cro~povidone tmanuf~ctured by ISP Inc.), citrlc acld snd ~p~tame, and g~anulation w~ carrled Dut uying water, whereln scopolalnin hydrobromlde was dis~olv~d in 200 ml of water. After magnesium ~tearate S ~0.~) waR ~dded to the re~ultant g~anulen, the mlxtu~e wa~ compr~s~lon-mol~ed with a rotary ~ype t~bletting m~chine (m~nuf~ctured by Ki~usui Selsaku~ho Co., Ltd.) a punch hav~ng A b~veled edge, 10 mm in di~meter, at A
moldlng pr~ur~ of 0.8 ton/cm2, to provide t~blet~
each weighlng 400 mg.
Mea~ . nt was earried out for ~ardne~s and ~uccal dissolution t~me o~ ~he obt~ined tablet~. The re~ult~ are shown in ~able 6.
Ta~le 5 ~ormul~ Example 5 Comp~rat~ve Ex~mple 5 Meclizine -31.25 31.25 hydr~chlorl~e Scopolamlne 0.1~ 0.16 hyd obromlde Caffeine 12.S 12.5 Vit~unln ~6 6.25 6.25 Erythritol ~44.~4 34~.34 Low sub~ltuted - 75 zs hydroxypropyl~ollu~ose Cry~t~ ne cellulo~e 75 Crospo~i~on~ 25 25 Cltric acid 5.0 5-0 Aspartame - 0.5 0 5 Total 500 0g 504.0g 97~10~21~ 19~00~;TAKEDA PATENTS OSAKA Fetherst~n ; 8163006601;#22/27 , lg Ta~le 6 ~hy31cal prope~ty ~xAmple 5 Camparative ~x~mple S
Hsrdne~ ~kg) 6.l 6.7 ~ucc~l dis~olutlon 2 ~me ~e~ond ~xample 6 In ~a~le 7, there i~ shown the compo~ition o~ the - prep~ratlon of Example 6 of the pre~ent inventlon.
A flu1dlzed-~ed granulat~r ~owrex Co., ~td. LABl) we.8 ~:h~rg~d with the med$c$nal ingredlents, erythrltol (m~nufactured by Nlkken Ch~m~cal Co., Ltd.), crystalLLne ce1lulose ~m~nufsetured ~y A~ahi ~hemlc~
Co., Ltd.), c$t~ic acld, a~pa~t~me and Y0llow No. S
hlumlnum l~ke, and gra~ul~tlon was c~r1ed out u~ing w~ter, whoroln a ~olution of scopol~mine hydro~ ~ 1de in 200 ml of water ~ by ~pr~ying. Aftor crospo~idone (manufactu~ed b~ ISP Inc.), llght anhydrou~ 811icic acld, t-menthol ~nd magn~
stear~to (O.5~) were addod to the re~ultant granule~, the ~ixtu~e wa~ .cc~npre~ion-molded wLth a rot~ry type tabletting mAchin~ ~anuf~ctured by Kikusul Sei~akusho co., Ltd.) with ~ punch h~vlng a bevnl~d edge, lO snm in di~meter, ~t a ~olding pres~ure of 0.8 ton/cma, to provlde tablets e~çh welghing 400 m~.
Me~ur~mont was cArried out for hardne~ and ~uccal ~is~olution ~ime of the obt~ined tablet~. ~he re4ult~ are sho~n ~n T~b~e 3.
'9~10~21~ 19~00~;TA~EDA PATENTS OSAKA Fetherst~n ; 8163006601;#23~2~
.
~able 7 Formul~ Example 6 M~clizino hydrochlorlde . 25.0 Scopolamine hydrobromide 0.~5 Erythritol 640.O
Cry~t~lllne cellulo~e ~0 . 55 Cr ~_~oi~idone 40 Citric ac$~ 8 . O
A~p~rta~e 1.2 Light 8nhydrou~ c ~cid1.~
M~qne~lum ~te~rate 4.0 Yellow No. S aluminum lake q.~.
~-Menthol g. B .
~ot~l 80~.0g Table 8 Phy~lcal p ope~Ly Example 6 Hardne~8 (kg) ~7 ~uccal d~olu~ion time (~ç~ond) 23 ~he solid pharm~ceutical prep~r~tion~ ~uCh a~
bu~cal dl~olutlon ~ype ta~le~ ~f the preaent lnYention hAve excellent intrabu~c~l di~integrabllity or dl~olubility, ~nd there~o~e, they are ea~lly ~0 ad~in~tered an~ inge~ted. Fur~her, slnce they have an appropr~ate ~treng~h, they ~e excellent in long shelf llfo or s~billty. Accord~ngly, the ~olid ph~rm~ceutical prepAr~tions can ~e advantagqou~ly u~ed for the ~L~ve~t~on o~ tre~tment ~f di~e~6es in p~tient~, p~rticul~ly ~ged o~ pod~atric p~tient~.
moldlng pr~ur~ of 0.8 ton/cm2, to provide t~blet~
each weighlng 400 mg.
Mea~ . nt was earried out for ~ardne~s and ~uccal dissolution t~me o~ ~he obt~ined tablet~. The re~ult~ are shown in ~able 6.
Ta~le 5 ~ormul~ Example 5 Comp~rat~ve Ex~mple 5 Meclizine -31.25 31.25 hydr~chlorl~e Scopolamlne 0.1~ 0.16 hyd obromlde Caffeine 12.S 12.5 Vit~unln ~6 6.25 6.25 Erythritol ~44.~4 34~.34 Low sub~ltuted - 75 zs hydroxypropyl~ollu~ose Cry~t~ ne cellulo~e 75 Crospo~i~on~ 25 25 Cltric acid 5.0 5-0 Aspartame - 0.5 0 5 Total 500 0g 504.0g 97~10~21~ 19~00~;TAKEDA PATENTS OSAKA Fetherst~n ; 8163006601;#22/27 , lg Ta~le 6 ~hy31cal prope~ty ~xAmple 5 Camparative ~x~mple S
Hsrdne~ ~kg) 6.l 6.7 ~ucc~l dis~olutlon 2 ~me ~e~ond ~xample 6 In ~a~le 7, there i~ shown the compo~ition o~ the - prep~ratlon of Example 6 of the pre~ent inventlon.
A flu1dlzed-~ed granulat~r ~owrex Co., ~td. LABl) we.8 ~:h~rg~d with the med$c$nal ingredlents, erythrltol (m~nufactured by Nlkken Ch~m~cal Co., Ltd.), crystalLLne ce1lulose ~m~nufsetured ~y A~ahi ~hemlc~
Co., Ltd.), c$t~ic acld, a~pa~t~me and Y0llow No. S
hlumlnum l~ke, and gra~ul~tlon was c~r1ed out u~ing w~ter, whoroln a ~olution of scopol~mine hydro~ ~ 1de in 200 ml of water ~ by ~pr~ying. Aftor crospo~idone (manufactu~ed b~ ISP Inc.), llght anhydrou~ 811icic acld, t-menthol ~nd magn~
stear~to (O.5~) were addod to the re~ultant granule~, the ~ixtu~e wa~ .cc~npre~ion-molded wLth a rot~ry type tabletting mAchin~ ~anuf~ctured by Kikusul Sei~akusho co., Ltd.) with ~ punch h~vlng a bevnl~d edge, lO snm in di~meter, ~t a ~olding pres~ure of 0.8 ton/cma, to provlde tablets e~çh welghing 400 m~.
Me~ur~mont was cArried out for hardne~ and ~uccal ~is~olution ~ime of the obt~ined tablet~. ~he re4ult~ are sho~n ~n T~b~e 3.
'9~10~21~ 19~00~;TA~EDA PATENTS OSAKA Fetherst~n ; 8163006601;#23~2~
.
~able 7 Formul~ Example 6 M~clizino hydrochlorlde . 25.0 Scopolamine hydrobromide 0.~5 Erythritol 640.O
Cry~t~lllne cellulo~e ~0 . 55 Cr ~_~oi~idone 40 Citric ac$~ 8 . O
A~p~rta~e 1.2 Light 8nhydrou~ c ~cid1.~
M~qne~lum ~te~rate 4.0 Yellow No. S aluminum lake q.~.
~-Menthol g. B .
~ot~l 80~.0g Table 8 Phy~lcal p ope~Ly Example 6 Hardne~8 (kg) ~7 ~uccal d~olu~ion time (~ç~ond) 23 ~he solid pharm~ceutical prep~r~tion~ ~uCh a~
bu~cal dl~olutlon ~ype ta~le~ ~f the preaent lnYention hAve excellent intrabu~c~l di~integrabllity or dl~olubility, ~nd there~o~e, they are ea~lly ~0 ad~in~tered an~ inge~ted. Fur~her, slnce they have an appropr~ate ~treng~h, they ~e excellent in long shelf llfo or s~billty. Accord~ngly, the ~olid ph~rm~ceutical prepAr~tions can ~e advantagqou~ly u~ed for the ~L~ve~t~on o~ tre~tment ~f di~e~6es in p~tient~, p~rticul~ly ~ged o~ pod~atric p~tient~.
Claims (17)
1. A solid pharmaceutical preparation which comprises (i) a pharmaceutically active ingredient, (ii) erythritol, (iii) crystalline cellulose and (iv) a disintegrant.
2. A solid pharmaceutical preparation as claimed in claim 1 which is capable of buccal disintegration or dissolution.
3. A solid pharmaceutical preparation as claimed in claim 1, which further comprises mannitol.
4. A solid pharmaceutical preparation as claimed in claim 1, wherein the disintegrant is crospovidone.
5. A solid pharmaceutical preparation as claimed in claim 1, wherein erythritol is contained in a proportion of 5-90 parts by weight, based on 100 parts by weight of the solid pharmaceutical preparation.
6. A solid pharmaceutical preparation as claimed in claim 1, wherein the crystalline cellulose is contained in a proportion of 3-50 parts by weight, based on 100 parts by weight of the solid pharmaceutical preparation.
7. A solid pharmaceutical preparation as claimed in claim 1, wherein the disintegrant is contained in a proportion of 1-10 parts by weight, based on the solid pharmaceutical preparation.
8. A solid pharmaceutical preparation as claimed in claim 1, wherein the ingredients, (i) a pharmaceutically active ingredient, (ii) erythritol, (iii) crystalline cellulose and (iv) a disintegrant, are uniformly mixed.
9. A solid pharmaceutical preparation as claimed in claim 1, which is a tablet.
10. A solid pharmaceutical preparation capable of buccal disintegration or dissolution, which comprises 0.3-50 parts by weight of (i) pharmaceutically active ingredient, 50-80 parts by weight of (ii) erythritol, and 5-20 parts by weight of (iii) crystalline cellulose and 3-7 parts by weight of (iv) a disintegrant.
11. A solid pharmaceutical preparation as claimed in any one of claims 1 to 10, wherein the pharmaceutically active ingredient is an antidinics or a drug for kinetosis or motion sickness.
12. A method of improving buccal disintegration or dissolution of a solid pharmaceutical preparation containing (i) a pharmaceutically active ingredient, which comprises incorporating (ii) erythritol, (iii) crystalline cellulose and (iv) a disintegrant in combination in the solid pharmaceutical preparation.
13. Use of a combination of (ii) erythritol, (iii) crystalline cellulose and (iv) a disintegrant for the production of a solid pharmaceutical preparation comprising (i) a pharmaceutically active ingredient, with improved buccal disintegrability and/or dissolubility.
14. Use of a composition comprising (i) a pharmaceutically active ingredient, (ii) erythritol, (iii) crystalline cellulose and (iv) a disintegrant for the production of a solid pharmaceutical preparation improved with buccal disintegrability and/or dissolubility.
15. A method of making a solid pharmaceutical preparation, which comprises:
blending a mixture of (i) a pharmaceutically active ingredient, (ii) erythritol, (iii) crystalline cellulose and (iv) a disintegrant, and producing the solid pharmaceutical preparation from the mixture.
blending a mixture of (i) a pharmaceutically active ingredient, (ii) erythritol, (iii) crystalline cellulose and (iv) a disintegrant, and producing the solid pharmaceutical preparation from the mixture.
16. The method according to claim 15, wherein the solid preparation dissolves completely in solely buccal saliva within 1 minute of administration to a patient.
17. A tablet adapted for buccal disintegration or dissolution in the oral cavity, which comprises:
(i) 0.3-30 parts by weight of a pharmaceutically active or medicinal ingredient;
(ii) 50-80 parts by weight of erythritol;
(iii) 5-20 parts by weight of crystalline cellulose; and (iv) 1-10 parts by weight of a super disintegrant selected from the group consisting of crospovidone, croscarmellose, croscarmellose sodium, and carmellose calcium, each per 100 parts by weight of the tablet, wherein the ingredients (i), (ii), (iii) and (iv) are intimately and uniformly mixed and formed into the tablet which has a hardness of from about 2 to about 15 kg and completely dissolves by buccal saliva in from about 0.1 to about 1.0 minute when taken by a healthy male adult.
(i) 0.3-30 parts by weight of a pharmaceutically active or medicinal ingredient;
(ii) 50-80 parts by weight of erythritol;
(iii) 5-20 parts by weight of crystalline cellulose; and (iv) 1-10 parts by weight of a super disintegrant selected from the group consisting of crospovidone, croscarmellose, croscarmellose sodium, and carmellose calcium, each per 100 parts by weight of the tablet, wherein the ingredients (i), (ii), (iii) and (iv) are intimately and uniformly mixed and formed into the tablet which has a hardness of from about 2 to about 15 kg and completely dissolves by buccal saliva in from about 0.1 to about 1.0 minute when taken by a healthy male adult.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP290606/1996 | 1996-10-31 | ||
| JP29060696 | 1996-10-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2219705A1 true CA2219705A1 (en) | 1998-04-30 |
Family
ID=17758187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002219705A Abandoned CA2219705A1 (en) | 1996-10-31 | 1997-10-30 | Solid pharmaceutical preparation |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US5958453A (en) |
| EP (1) | EP0839526A3 (en) |
| CN (1) | CN1181237A (en) |
| CA (1) | CA2219705A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10051847B1 (en) | 2014-06-11 | 2018-08-21 | Bert E. Smith | Fishing lures and fishing lure production methods and uses |
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1380308B1 (en) * | 1996-07-12 | 2008-07-09 | Daiichi Pharmaceutical Co., Ltd. | Quickly disintegrable compression-molded materials and process for producing the same |
| US5958453A (en) * | 1996-10-31 | 1999-09-28 | Takeda Chemical Industries, Ltd. | Solid pharmaceutical preparation with improved buccal disintegrability and/or dissolubility |
| US6024981A (en) * | 1997-04-16 | 2000-02-15 | Cima Labs Inc. | Rapidly dissolving robust dosage form |
| TW580397B (en) | 1997-05-27 | 2004-03-21 | Takeda Chemical Industries Ltd | Solid preparation |
| WO1999004758A1 (en) * | 1997-07-25 | 1999-02-04 | Elan Corporation Plc | A process for the preparation of a granulate suitable to the preparation of rapidly disintegrable mouth-soluble tablets |
| US6465009B1 (en) * | 1998-03-18 | 2002-10-15 | Yamanouchi Pharmaceutical Co., Ltd. | Water soluble polymer-based rapidly dissolving tablets and production processes thereof |
| US6974590B2 (en) | 1998-03-27 | 2005-12-13 | Cima Labs Inc. | Sublingual buccal effervescent |
| US20030091629A1 (en) | 1998-03-27 | 2003-05-15 | Cima Labs Inc. | Sublingual buccal effervescent |
| PT1121103E (en) * | 1998-05-18 | 2007-02-28 | Takeda Pharmaceutical | Orally disintegrable tablets comprising a benzimidazole |
| ATE481090T1 (en) * | 1998-07-28 | 2010-10-15 | Takeda Pharmaceutical | EASILY DISSOLVING SOLID PREPARATION |
| FR2784895B1 (en) * | 1998-10-23 | 2004-12-17 | Gattefosse Ets Sa | MASK TASTE CHEWABLE TABLET AND IMMEDIATE RELEASE OF THE ACTIVE INGREDIENT AND MANUFACTURING METHOD |
| FR2785538B1 (en) * | 1998-11-06 | 2004-04-09 | Prographarm Laboratoires | PERFECTED QUICK DELIVERY TABLET |
| AU3574500A (en) * | 1999-03-25 | 2000-10-16 | Yuhan Corporation | Rapidly disintegrable tablet for oral administration |
| KR20010006835A (en) * | 1999-03-25 | 2001-01-26 | 김선진 | Rapidly disintegrable tablet for oral administration |
| CA2374760A1 (en) * | 1999-06-18 | 2000-12-28 | Takeda Chemical Industries, Ltd. | Quickly disintegrating solid preparations |
| CA2380449A1 (en) * | 1999-08-17 | 2001-02-22 | Novartis Consumer Health S.A. | Rapidly dissolving dosage form and process for making same |
| US9522217B2 (en) | 2000-03-15 | 2016-12-20 | Orbusneich Medical, Inc. | Medical device with coating for capturing genetically-altered cells and methods for using same |
| US20070141107A1 (en) * | 2000-03-15 | 2007-06-21 | Orbusneich Medical, Inc. | Progenitor Endothelial Cell Capturing with a Drug Eluting Implantable Medical Device |
| US8088060B2 (en) | 2000-03-15 | 2012-01-03 | Orbusneich Medical, Inc. | Progenitor endothelial cell capturing with a drug eluting implantable medical device |
| EP1269995A1 (en) * | 2000-03-27 | 2003-01-02 | Kyowa Hakko Kogyo Co., Ltd. | Easy-to-take granule |
| CN1638739A (en) * | 2000-08-18 | 2005-07-13 | 法玛西雅厄普约翰美国公司 | Compound for treating assuetude disturbance |
| WO2002024166A1 (en) * | 2000-09-22 | 2002-03-28 | Sumitomo Pharmaceuticals Company, Limited | Oral preparations with favorable disintegration characteristics |
| AU2001294192A1 (en) * | 2000-10-06 | 2002-04-22 | Takeda Chemical Industries Ltd. | Solid preparations |
| US7049283B2 (en) * | 2000-12-06 | 2006-05-23 | Novartis Ag | Pharmaceutical compositions for the oral delivery of pharmacologically active agents |
| US6544552B2 (en) | 2001-01-11 | 2003-04-08 | Particle And Coating Technologies, Inc. | Method of producing porous tablets with improved dissolution properties |
| IL157320A0 (en) * | 2001-02-08 | 2004-02-19 | Pharmacia Corp | Rapid-onset medicament for the treatment of sexual dysfunction |
| US20030224047A1 (en) * | 2001-02-15 | 2003-12-04 | Franz G. Andrew | Levothyroxine compositions and methods |
| WO2002064093A2 (en) | 2001-02-15 | 2002-08-22 | King Pharmaceuticals, Inc. | Stabilized pharmaceutical and thyroid hormone compositions and method of preparation |
| US6555581B1 (en) | 2001-02-15 | 2003-04-29 | Jones Pharma, Inc. | Levothyroxine compositions and methods |
| US20030032675A1 (en) * | 2001-02-15 | 2003-02-13 | Franz G. Andrew | Manufacture of thyroid hormone tablets having consistent active moiety amounts |
| US6998139B2 (en) * | 2001-03-15 | 2006-02-14 | Astellas Pharma Inc. | Bitterness-reduced intrabuccally quick disintegrating tablets and method for reducing bitterness |
| WO2002092058A1 (en) * | 2001-05-15 | 2002-11-21 | Takeda Chemical Industries, Ltd. | Rapidly disintegratable solid preparation |
| US20030190349A1 (en) * | 2001-08-10 | 2003-10-09 | Franz G. Andrew | Methods of stabilizing pharmaceutical compositions |
| US20030180353A1 (en) * | 2001-08-10 | 2003-09-25 | Franz G. Andrew | Stabilized pharmaceutical compositions |
| US20030198671A1 (en) * | 2001-08-10 | 2003-10-23 | Franz G. Andrew | Levothyroxine compositions having unique plasma AUC properties |
| US20030198667A1 (en) * | 2001-08-10 | 2003-10-23 | Franz Andrew G. | Methods of producing dispersible pharmaceutical compositions |
| US20030195253A1 (en) * | 2001-08-14 | 2003-10-16 | Franz G. Andrew | Unadsorbed levothyroxine pharmaceutical compositions, methods of making and methods of administration |
| US20030199587A1 (en) * | 2001-08-14 | 2003-10-23 | Franz G. Andrew | Levothyroxine compositions having unique Cmax properties |
| US20030198672A1 (en) * | 2001-08-14 | 2003-10-23 | Franz G. Andrew | Levothyroxine compositions having unique triidothyronine plasma AUC properties |
| US7101569B2 (en) | 2001-08-14 | 2006-09-05 | Franz G Andrew | Methods of administering levothyroxine pharmaceutical compositions |
| US20030199586A1 (en) * | 2001-08-14 | 2003-10-23 | Franz G. Andrew | Unique levothyroxine aqueous materials |
| US20030203967A1 (en) * | 2001-08-14 | 2003-10-30 | Franz G. Andrew | Levothyroxine compositions having unique Tmax properties |
| US20030180356A1 (en) * | 2001-10-29 | 2003-09-25 | Franz G. Andrew | Levothyroxine compositions having unique triiodothyronine Tmax properties |
| US7118765B2 (en) | 2001-12-17 | 2006-10-10 | Spi Pharma, Inc. | Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms |
| JP2003238393A (en) * | 2002-02-15 | 2003-08-27 | Otsuka Pharmaceut Co Ltd | Tablet with improved tableting property and method for producing the same |
| GB0217930D0 (en) * | 2002-08-02 | 2002-09-11 | Glycologic Ltd | A chemical carrier |
| AU2003254914A1 (en) * | 2002-08-12 | 2004-03-03 | Kyowa Hakko Kogyo Co., Ltd. | Amino acid-containing chewable |
| EP1545521A2 (en) * | 2002-10-04 | 2005-06-29 | Pharmacia Corporation | Compositions and methods for treating sexual dysfunction |
| WO2004089344A1 (en) * | 2003-04-01 | 2004-10-21 | Ohara Chmical Industries, Ltd. | Process for producing tablet |
| US20070092583A1 (en) * | 2003-04-30 | 2007-04-26 | Tim Clarot | Cold remedy composition comprising zinc salts |
| EP1620075B1 (en) * | 2003-05-07 | 2020-06-24 | Samyang Biopharmaceuticals Corporation | Highly plastic granules for making fast melting tablets |
| ITRM20030288A1 (en) * | 2003-06-10 | 2004-12-11 | Valerio Cioli | SUBLINGUAL ADMINISTRATION OF NON STEROID INFLAMMATORY (NSAID) |
| US7838029B1 (en) | 2003-07-31 | 2010-11-23 | Watson Laboratories, Inc. | Mirtazapine solid dosage forms |
| US7390503B1 (en) | 2003-08-22 | 2008-06-24 | Barr Laboratories, Inc. | Ondansetron orally disintegrating tablets |
| US20050065172A1 (en) * | 2003-09-23 | 2005-03-24 | Shah Indukumar G. | Solid dosage form comprising caffeine |
| US20050067163A1 (en) * | 2003-09-25 | 2005-03-31 | George Flint R. | Monobore release for tubing conveyed perforating |
| US20050113394A1 (en) * | 2003-11-26 | 2005-05-26 | Wood Allen W. | Pharmaceutical compositions |
| US7670624B2 (en) * | 2004-01-29 | 2010-03-02 | Astella Pharma Inc. | Gastrointestinal-specific multiple drug release system |
| US20060198885A1 (en) * | 2005-02-22 | 2006-09-07 | Sun Pharmaceutical Industries Ltd. | Oral pharmaceutical composition |
| EP1897558B1 (en) * | 2005-06-09 | 2013-09-04 | Norgine BV | Solid preparation of 2-hexadecyloxy-6-methyl-4h-3,1-benzoxazin-4-one |
| US20070020186A1 (en) | 2005-07-22 | 2007-01-25 | Alpex Pharma S.A. | Solid dosage formulations of narcotic drugs having improved buccal adsorption |
| JP5366233B2 (en) * | 2005-08-10 | 2013-12-11 | 塩野義製薬株式会社 | Orally disintegrating tablets |
| US7811604B1 (en) | 2005-11-14 | 2010-10-12 | Barr Laboratories, Inc. | Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same |
| BRPI0620185B8 (en) * | 2005-12-21 | 2021-05-25 | Basf Se | pharmaceutical formulation, tablets, and, process for preparing a pharmaceutical formulation |
| ITMI20061117A1 (en) * | 2006-06-09 | 2007-12-10 | Michele Bonanomi | A PHARMACEUTICAL COMPOSITION FOR THE SUBLINGUAL ADMINISTRATION OF VACCINI METHOD FOR ITS PREPARATION AND USES |
| ES2302650B1 (en) * | 2007-01-11 | 2009-02-16 | Tedec-Meiji Farma, S.A. | COMPOSITION OF FAST DISINTEGRATION IN THE ORAL CAVITY. |
| JP5537927B2 (en) * | 2007-03-13 | 2014-07-02 | 大日本住友製薬株式会社 | Orally disintegrating tablets |
| BRPI0809205B8 (en) * | 2007-03-29 | 2021-05-25 | Daiichi Sankyo Co Ltd | pharmaceutical composition |
| CA2688389A1 (en) | 2007-06-06 | 2008-12-11 | Basf Se | Pharmaceutical formulation for the production of rapidly disintegrating tablets |
| WO2008148731A1 (en) | 2007-06-06 | 2008-12-11 | Basf Se | Pharmaceutical formulation for the production of rapidly disintegrating tablets |
| JP5627455B2 (en) | 2007-06-06 | 2014-11-19 | ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ | Pharmaceutical formulations for the production of fast-disintegrating tablets |
| EP2161021B1 (en) * | 2007-06-07 | 2017-03-08 | Sato Pharmaceutical Co. Ltd. | Medicinal film preparation with rapidly dissolving property and flexibility |
| WO2009041651A1 (en) * | 2007-09-27 | 2009-04-02 | Mitsubishi Tanabe Pharma Corporation | Rapidly disintegrating solid preparation |
| JP5258268B2 (en) * | 2007-11-19 | 2013-08-07 | フロイント産業株式会社 | Method for producing spherical particles |
| PT2246051E (en) * | 2008-01-31 | 2014-01-07 | Kyorin Seiyaku Kk | Method for production of orally rapidly disintegrating tablet comprising imidafenacin as active ingredient |
| AU2009219292B2 (en) * | 2008-02-28 | 2014-02-27 | R.P. Scherer Technologies, Llc | Process to minimize polymorphism |
| US20100190739A1 (en) * | 2008-12-15 | 2010-07-29 | Fleming And Company, Pharmaceuticals | Rapidly Dissolving Vitamin Formulation and Methods of Using the Same |
| EP2405905B1 (en) | 2009-03-09 | 2016-06-29 | SPI Pharma, INC. | Highly compactable and durable direct compression excipients and excipient systems |
| EP2510950B1 (en) | 2009-12-11 | 2018-11-28 | Sumitomo Dainippon Pharma Co., Ltd. | Dry-coated orally disintegrating tablet |
| KR101792299B1 (en) | 2010-03-19 | 2017-10-31 | 다이이찌 산쿄 가부시키가이샤 | Method for improving dissolution of anticoagulant agent |
| CN103384517A (en) | 2010-12-22 | 2013-11-06 | 巴斯夫欧洲公司 | Rapidly disintegrating, solid coated dosage form |
| US8715729B2 (en) | 2010-12-22 | 2014-05-06 | Basf Se | Rapidly disintegrating, solid coated dosage form |
| CN103415284B (en) | 2011-03-09 | 2016-12-07 | 巴斯夫欧洲公司 | Pharmaceutical formulation for producing rapidly disintegrating tablets |
| KR101940840B1 (en) | 2011-08-10 | 2019-01-21 | 다이이찌 산쿄 가부시키가이샤 | Pharmaceutical composition containing diamine derivative |
| US9744135B2 (en) | 2015-02-27 | 2017-08-29 | Deseret Laboratories, Inc. | Fast disintegrating compositions and tablets thereof |
| EP3135272A1 (en) | 2015-08-31 | 2017-03-01 | Basf S.A. | Compositions for mouth wash in the form of tablets |
| EP4265241A1 (en) | 2022-04-20 | 2023-10-25 | Bilim Ilac Sanayii Ve Ticaret A.S. | Tablet formulations for the treatment of urinary system infections and method for the preparation of such formulations |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1548022A (en) * | 1976-10-06 | 1979-07-04 | Wyeth John & Brother Ltd | Pharmaceutial dosage forms |
| US5030447A (en) * | 1988-03-31 | 1991-07-09 | E. R. Squibb & Sons, Inc. | Pharmaceutical compositions having good stability |
| US4910023A (en) * | 1988-06-09 | 1990-03-20 | Warner-Lambert Company | Drug in combination with flavor masking agent and method for making same |
| GB8824392D0 (en) * | 1988-10-18 | 1988-11-23 | Ciba Geigy Ag | Dispersible formulation |
| IT1238072B (en) * | 1990-01-19 | 1993-07-03 | Sclavo Spa | PHARMACEUTICAL COMPOSITIONS AND DOSAGE FORMS FOR ORAL ADMINISTRATION OF CALCITONIN |
| US5316772A (en) * | 1990-12-19 | 1994-05-31 | Solvay & Cie, S.A. (Societe Anonyme) | Bilayered oral pharmaceutical composition with pH dependent release |
| EP0553777B1 (en) * | 1992-01-29 | 2002-04-24 | Takeda Chemical Industries, Ltd. | Fast dissolving tablet and its production |
| IL110376A (en) * | 1993-08-02 | 1998-08-16 | Bristol Myers Squibb Co | Pharmaceutical compositions containing ifetroban salts and methods for the preparation thereof |
| CA2179382C (en) * | 1994-01-31 | 2009-11-10 | Takao Mizumoto | Intrabuccally dissolving compressed moldings and production process thereof |
| JPH0827033A (en) * | 1994-07-14 | 1996-01-30 | Nikken Chem Co Ltd | Erythritol-containing solid agent |
| US5958453A (en) * | 1996-10-31 | 1999-09-28 | Takeda Chemical Industries, Ltd. | Solid pharmaceutical preparation with improved buccal disintegrability and/or dissolubility |
-
1997
- 1997-10-29 US US08/960,353 patent/US5958453A/en not_active Expired - Lifetime
- 1997-10-29 EP EP97118757A patent/EP0839526A3/en not_active Withdrawn
- 1997-10-30 CA CA002219705A patent/CA2219705A1/en not_active Abandoned
- 1997-10-30 CN CN97121234A patent/CN1181237A/en active Pending
-
1999
- 1999-07-12 US US09/351,253 patent/US6248357B1/en not_active Expired - Lifetime
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10051847B1 (en) | 2014-06-11 | 2018-08-21 | Bert E. Smith | Fishing lures and fishing lure production methods and uses |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1181237A (en) | 1998-05-13 |
| EP0839526A3 (en) | 1999-01-07 |
| EP0839526A2 (en) | 1998-05-06 |
| US5958453A (en) | 1999-09-28 |
| US6248357B1 (en) | 2001-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2219705A1 (en) | Solid pharmaceutical preparation | |
| CA2257431C (en) | Fast-dissolving galanthamine hydrobromide tablet | |
| US6955821B2 (en) | Sustained release formulations of guaifenesin and additional drug ingredients | |
| US6399100B1 (en) | Controlled release pharmaceutical compositions containing tiagabine | |
| EP0218148B1 (en) | Slow-release pharmaceutical composition | |
| US6372252B1 (en) | Guaifenesin sustained release formulation and tablets | |
| US8318203B2 (en) | Form of administration of racecadotril | |
| CA2182004C (en) | Film coated tablet of paracetamol and domperidone | |
| AU2005263958B2 (en) | Anti-histaminic composition | |
| KR100846945B1 (en) | Swallow tablet comprising paracetamol | |
| NZ220769A (en) | Compositions of ketotifen (4-(1-methyl-4-piperidylidene)- 4h-benzo(4,5)cyclohepta(1,2-b)thiophen-10-9(h)-one) | |
| US6110493A (en) | Terazosin capsules | |
| GB2154874A (en) | Bromocriptine compositions | |
| US5441933A (en) | Pharmaceutical compositions and dosage forms for the oral administration of calcitonin | |
| AU780379B2 (en) | Orally distintegrating composition comprising mirtazapine | |
| CA2299464C (en) | Controlled release pharmaceutical compositions containing tiagabine | |
| WO2016084099A1 (en) | Soft gelatin capsule composition of anti-tussive agents | |
| AU2003224419A1 (en) | Orally administrable pharmaceutical formulation | |
| KR100590622B1 (en) | Stabile compositions comprising levosimendan and alginic acid | |
| CA1256374A (en) | Bromocriptine compositions | |
| KR920008817B1 (en) | Process for the preparing pharmaceutical formulations with controlled release of the active substance | |
| JPH10226644A (en) | Medicinal composition | |
| EP3865125A1 (en) | Pharmaceutical composition comprising eliglustat | |
| US20030158263A1 (en) | Orally administrable pharmaceutical formulation | |
| JPS6024766B2 (en) | sustained release antibiotic tablets |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |